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1. ABBREVIATIONS 
ACAT  : Acyl coenzyme A Cholesterol Acyltransferase  
AE1  : Anion Exchanger 1  
AIF  :  Apoptosis-inducing factor 
Akt   : Protein Kinase B 
AMPA  : alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
AMPK  :  Adenosine monophosphate-activated protein kinase 
ANOVA : Analysis of variance  
APC  : Adenomatous Polyposis Coli  
ATP  :  Adenosine triphosphate 
BSA  : Bovine serum albumin 
Ca2+  : Calcium 
Cl-   : Chloride 
CNQX  :  6-cyano-7-nitroquinoxaline-2, 3-Dione 
CO2   : Carbon dioxide 
COX  :  Cyclooxygenase 
CTL  : Cytotoxic T lymphocytes  
DCFDA : 2’,7’ dichlorodihydrofluorescein diacetate  
dl  : Deciliter 
DMSO  : Dimethylsulfoxide  
DNA  : Deoxyribonucleic acid 
DNQX  :  6,7-dinitro-quinoxaline-2,3-dione 
EDTA  :  Ethylenediaminetetraacetic acid 
EGTA  :  glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid 
EIPA  : Ethylisopropylamiloride 
EPO  :  Erythropoietin 
ERK  :  Extracellular regulated protein kinase 
FACS  :  Fluorescence-activated cell sorting 
FITC  :  Fluorescein isothyocyanate 
FL  :  Fluorescence channel 
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fL  : Femtolitter 
FSC  :  Forward scatter 
G  :  Gram 
Geo mean : Geometric mean 
GLUT  :  Glucose transporter 
G6PD  :  Glucose-6-Phosphat-Dehydrogenas 
H  :  Hour 
Hb  :  Hemogblobin 
HClO4  : Perchloric acid  
HEPES :  32 N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid 
HUVEC : Human umbilical vein endothelial cells  
ICAM-4 :  Intercellular Adhesion Molecule-4  
IgG  : Immunoglobulin G 
IgM  : Immunoglobulin M 
JAK  :  Janus kinase 
JNK  : Jun N-terminale Kinase  
K+  : Potassium 
Kg  : Kilogram 
KHCO3  : Potassium bicarbonate 
L  : Liter 
MCV  : Mean cell volume 
MRP4  :  Multi drug resistance protein 4 
mM  :  Millimolar 
Na+   : Sodium 
NBQX :  1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-benzo[f]quinoxaline-7 -   
                                     sulfonamide 
NF  :  Nuclear factor 
NHE  :  Na+/H+ exchanger 
NPPB  :     Natriuretic peptide B 
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NQO1  : NAD(P)H dehydrogenase, quinone 1 
O2  : Oxygen 
nM  :  Nanomolar  
NMDG :  N-methyl-D-glucamine 
NO  :  Nitric oxide 
OTA  : Ochratoxin A 
PAF  :  Platelet activating factor 
PBS  :  Phosphate-buffered saline 
PDK1  :  Pyruvate dehydrogenase kinase 1 
PGE2  : Prostaglandin E2 
PKA  :    Protein kinase A 
PLA   : Phospholipase A 
PNQX  :  1,4,7,8,9,10-hexahydro-9-methyl- 6 nitro-pyrido[3,4-f]-quinoxaline-2,3-   
                                     Dione 
PS  :  Phosphatidylserine 
RBC  : Red blood cell 
RR  : Rabdosia rubescens  
SEM  :  Standard error of mean 
SM  : Sphingomyelin 
tBOOH : t-butyl hydroperoxide  
TRPC6 :  Transient receptor potential cation channel 6  
ZEA  : Zearalenone 
zVAD  : Pancaspase inhibitor  
µg  :  Microgram 
µL  : Microliter 
µM  :  Micromole 
µm  : Micron 
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2. SUMMARY 
Erythrocytes are similar to nucleated cells in that they undergo suicidal death or eryptosis. 
Mechanism involved in eryptosis may depend on the activation of Ca2+-sensitive cation channels 
leading to increase intracellular Ca2+ activity. Enhanced cytosolic Ca2+ concentration stimulates 
phosphatidylserine exposure at the cell surface and cell shrinkage. Eryptosis is a physiological 
process which may have an important contribution in the limitation of erythrocyte survival. 
Excessive eryptosis due to stress, toxicity, diseases or defective compensatory mechanism may 
lead to anemia. The present observations determined the role of xenobiotics in the regulation of 
eryptosis as well as their toxic effects for erythrocytes. 
The first part of the study explored the mechanisms adopted by different foods born mycotoxins 
(enniatin A, ochratoxin A and zearalenone) in the triggering of eryptosis.  Exposure of 
erythrocytes for 48 hours to enniatin A (≥2.5µM) significantly increased [Ca2+]i, decreased 
[ATP]i, decreased forward scatter, triggered annexin-V-binding and elicited hemolysis. Decreased 
[ATP]i by glucose depletion for 48 hours was similarly followed by increased [Ca2+]i, decreased 
forward scatter and annexin-V-binding. Annexin-V-binding was blunted by Ca2+-removal, by the 
cation channel inhibitor amiloride (1mM), by the protein kinase C inhibitor staurosporine 
(500nM) but not by the pancaspase inhibitor zVAD (10µM). A 48 hour treatment of erythrocytes 
with ochratoxin A was followed by significant increase of Fluo3-fluorescencei (≥ 2.5 µM), 
increase of ceramide abundance (10 µM), decrease of forward scatter (≥ 5 µM) and increase of 
annexin-V-binding (≥ 2.5 µM). Ochratoxin A exposure slightly but significantly enhanced 
hemolysis (10 µM). Ochratoxin (10 µM) enhanced erythrocyte adhesion to HUVEC. Removal of 
extracellular Ca2+ significantly blunted, but did not abrogate ochratoxin A-induced annexin V 
binding. Similar to enniatin A and ochratoxin A, a 48 h treatment of erythrocytes with 
zearalenone (≥ 25 µM) was resulted into significant increase of [Ca2+]i, significant decrease of 
forward scatter, and significant increase of annexin-V-binding. The effect on annexin V binding 
was significantly blunted in the nominal absence of extracellular Ca2+. Zearalenone stimulates the 
suicidal erythrocyte death, an effect at least partially due to stimulation of Ca2+ entry. The present 
findings show that, all three mycotoxin (enniatin A, ochratoxin A and zearalenone) which  were 
previously reported to induce apoptotic cell death in nucleated cells, also under their in vivo 
plasma concentrations act as potent stimulators of suicidal death of erythrocytes despite the 
absence of gene expression and mitochondria. 
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The second part of the study explored the mechanisms involved in the eryptosis induced by 
therapeutically important phytochemicals (withaferin A, oridonin and dicoumarol). For 48 hour, 
erythrocytes were exposed to the three different phytochemicals with indicated concentrations 
leveling the range of their in vivo plasma levels. Withaferin A significantly decreased forward 
scatter (at ≥10 µM withaferin concentration) and increased [Ca2+]i (≥5 µM), ROS-formation (≥10 
µM) ceramide-formation (≥10 µM) as well as annexin-V-binding (≥5 µM). Withaferin A 
treatment was followed by slight but significant increase of hemolysis. Extracellular Ca2+ 
removal, amiloride, and the antioxidant N-acetyl-L-cysteine significantly blunted withaferin A-
triggered annexin-V-binding. Erythrocytes were exposed to oridonin. At concentration (≥25µM) 
oridonin significantly increased cytosolic Ca2+-concentration, increased ceramide formation, 
decreased forward scatter and triggered annexin V-binding (the latter in >20% of the 
erythrocytes). Oridonin did not decrease ATP concentration and hemolysed <5% of erythrocytes. 
The effects of oridonin on annexin V binding were partially reversed in the nominal absence of 
Ca2+ and by the addition of amiloride (1mM). Dicoumarol (≥10 µM) after incubation, 
significantly increased [Ca2+]i, enhanced cation channel activity, decreased forward scatter, 
triggered annexin-V-binding and elicited hemolysis. Following exposure to 30 µM dicoumarol, 
annexin-V-binding affected approximately 15%, and hemolysis 2% of treated erythrocytes. The 
stimulation of annexin-V-binding by dicoumarol was abrogated in the nominal absence of Ca2+. 
Collectively the data obtained from these studies reveal a completely novel effect of medicinally 
important phytochemicals (withaferin A, oridonin and dicoumarol) i.e the regulation of calcium-
dependent suicidal death erythrocyte death.   
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3. ZUSAMMENFASSUNG 
Erythrozyten können, ähnlich wie zellkernhaltige Zellen, in einen suizidalen Zelltod eintreten. 
Dieser Vorgang wird auch als „Eryptose“ bezeichnet. Die Mechanismen, die an der Eryptose 
beteiligt sind, hängen unter anderem von der Aktivierung Ca2+ abhängiger Kationenkanäle ab, 
was zu einer erhöhten intrazellulären Ca2+-Aktivität führt. Eine erhöhte cytosolische Ca2+-
Konzentration stimuliert die Umlagerung von Phosphatidylserin an die Zelloberfläche und führt 
zum Zellschrumpfen. Die Eryptose ist ein physiologischer Prozess, der dazu beiträgt, dass das 
Überleben beschädigter Erythrozyten limitiert wird. Eine verstärkte Eryptose aufgrund von Stress, 
toxischer Substanzen, Krankheiten oder nicht kompensatorischen Mechanismen können zu 
Anämie führen. Die hier präsentierten Beobachtungen zeigen die Rolle von Xenobiotika in der 
Regulation der Eryptose sowie deren toxische Effekte auf Erythrozyten. 
Der erste Teil der Studie untersuchte die Mechanismen verschiedener in Lebensmitteln 
vorhandenen Mycotoxinen (Enniatin A, Ochratoxin A und Zearalenon), die eine Eryptose 
auslösen. Die Inkubation von Erythrozyten für 48 Stunden mit Enniation A (≥2.5µM) erhöhte 
signifikant die intrazelluläre Ca2+-Konzentration und die Annexin-V-Bindung, erniedrigte 
signifikant [ATP] und den Forward Scatterund löste Hämolyse aus. Ein erniedrigter ATP-Gehalt 
nach Glukose-Depletion führte in ähnlicher Weise zu einer erhöhten Ca2+-Konzentration, 
erniedrigte das Forward Scatter und erhöhte die Annexin-V-Bindung. Die erhöhte Anzahl an 
Annexin-V-positiven Erythrozyten wurde durch das Entfernen von Ca2+ , durch den Kationen-
Kanal Inhibitor Amilorid (1mM) und durch den Protein-Kinase C Inhibitor Staurosporin (500 
nM) verringert, jedoch nicht durch den Pancaspase Inhibitor zVAD (10µM). Eine 48 stündige 
Behandlung der Erythrozyten mit Ochratoxin A hatte eine erhöhte Fluo3-Fluoreszenz, einen 
erhöhten Ceramid-Gehalt (10 µM), ein erniedrigtes Forward Scatter ((≥ 5 µM)) und eine erhöhte 
Annexin-V-Bindung (≥ 2.5 µM) zur Folge. Die Ochratoxin A-Exposition erhöhte schwach, aber 
dennoch signifikant, die Hämolyse (10 µM). Ochratoxin A (10 µM) erhöhte die Adhäsion der 
Erythrozyten an HUVEC-Zellen. Das Entfernen von extrazellulären Ca2+-Ionen erniedrigte zwar 
die mittels durch Ochratoxin A induzierte Annexin-V-Bindung, hebte den Effekt jedoch nicht auf. 
Ähnlich wie Enniatin A und Ochratoxin A, führte eine 48 stündige Inkubation der Erythrozyten 
mit Zearalenon (≥ 25 µM) zu einer erhöhten intrazellulären Ca2+]--Konzentration, zu einem 
erniedrigten Forward Scatter und zu einer signifikant erhöhten Annexin-V-Bindung. Der Effekt 
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auf die Annexin-V-Bindung wurde durch das Entfernen der extrazellulären Ca2+-Ionen signifikant 
abgeschwächt. Zearalenon stimuliert den suizidalen Erythrozytentod, ein Effekt, der zum Teil auf 
die Stimulation des Ca2+-Einstroms zurückzuführen ist.  
Die gegenwärtigen Beobachtungen zeigen, dass die drei Mycotoxine Enniatin A, Ochratoxin A 
und Zearalenon, von denen bekannt ist, dass sie den apoptotischen Zelltod in zellkernhaltigen 
Zellen auslösen, mit Konzentrationen im Bereich der in vivo gefundenenPlasmakonzentrationen 
auch als Stimulatoren des suizidalen Erythrozytentods fungieren, obwohl diese Zellen weder eine 
Genexpression noch Mitochondrien aufweisen. 
Der zweite Teil der Studie untersuchte die Mechanismen, die an der Eryptose durch die 
therapeutisch wirksamen Phytochemikalien Withaferin A, Oridonin und Dicoumarol beteiligt 
sind. Erythrozyten wurden für 48 Stunden den drei verschiedenen Phytochemikalien mit 
jeweiligen Konzentrationen, die sich im Bereich der Plasmakonzentrationen befanden, ausgesetzt. 
Withaferin A erniedrigte signifikant den Forward Scatter (≥10 µM) und erhöhte [Ca2+]i (≥5 µM), 
sowie die Bildung von ROS (≥10 µM), die Ceramid-Bildung (≥10 µM) und die Annexin-V-
Bindung (≥5 µM). Die Withaferin-Behandlung hatte eine schwache, aber signifikante Hämolyse 
zur Folge. Das Entfernen von extrazellulärem Ca2+, die Behandlung mit Amilorid und dem 
Antioxidans N-Acetyl-L-Cystein schwächte signifikant die Withaferin A- induzierte Annexin-V-
Bindung ab.  
Erythrozyten, die mit Oridonin behandelt wurden, zeigten bei einer Konzentration von ≥ 25µM 
Oridonin eine signifikant erhöhte cytosolische Ca 2+-Konzentration, verstärkte Ceramid-Bildung, 
ein vermindertes Forward Scatter und vermehrte Annexin-V-Bindung (in >20% der 
Erythrozyten). Oridonin erhöhte nicht die ATP-Konzentration und hämolysierte <5% der 
Erythrozyten. Der Effekt von Oridonin auf die Annexin-V-Bindung wurte teilweise durch das 
Entfernen von Ca2+ aus der Inkubationslösung und durch die Zugabe von Amilorid (1mM) 
aufgehoben. Dicoumarol (≥10 µM) erhöhte nach Inkubation signifikant  die Ca2+ -Konzentration 
sowie die Kationenkanal-Aktivität, erniedrigte das Forward Scatter und stimulierte die Annexin-
V-Bindung sowie die Hämolyse. Nach der Behandlung der Erythrozyten mit 30 µM Dicoumarol 
betrug die Annexin-V-Bindung ungefähr 15 % und die Hämolyse 2 %. Die Stimulation der 
Annexin-V-Bindung durch Dicoumarol wurde durch das Entfernen von extrazellulären Ca2+-
Ionen abgeschwächt.   Zusammengefasst zeigen die Daten dieser Studien einen neuartigen Effekt 
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medizinisch wichtiger Phytochemikalien, namentlichWithaferin A, Oridonin und Dicoumarol,, 
wie z.B.die Regulation des von Calcium abhängigen suizidalen Erythrozytentods. 
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4. INTRODUCTION 
4.1. Erythrocytes 
Erythrocytes are considered to be physiologically important and the most abundant cells in the 
human body and are mentioned in the literature as RBCs, red cells, red blood 
corpuscles, haematids and erythroid cells. Erythrocytes were for the first time identified by the 
Dutch biologist Jan Swammerdam, in 1658. Adult humans have approximately 2–3 × 1013 (20-30 
trillion) red blood cells which are about one quarter of the total cells in the body (Foller, Huber et 
al. 2008). Women have about 4 to 5 million and men about 5 to 6 million erythrocytes per µL of 
blood with exception of people living at high altitudes with low oxygen tension will have more. 
Red blood cells are more common than the other blood cells, in 1 µL of normal human blood 
there are about 4,000–11,000 white blood cells and 150,000–400,000 platelets (Pierige, Serafini 
et al. 2008). Erythrocytes have iron containing protein hemoglobin, which is principally 
responsible for transportation of O2 and CO2 in the body. Due to lack of nucleus and 
mitochondria, all the intracellular space in erythrocyte is available for gaseous transport 
(Tavassoli 1978). 
The formation of erythrocyte or erythropoiesis is stimulated in bone marrow by the renal hormone 
erythropoietin (EPO). Erythrocytes circulate in the blood for about 100–120 days before they are 
engulfed and their components are recycled by macrophages. Normal time for each circulation is 
about 20 seconds. Approximately 25 % of the cells in the human body comprises of red blood 
cells (Pierige, Serafini et al. 2008). 
The diameter and thickness of a typical human erythrocyte is 6–8 µm and 2µm respectively, 
smaller in size than most other human cells, having average volume of about 90 fL (Goodman, 
Kurdia et al. 2007). The red color of erythrocytes is due to the spectral characteristics of the 
hemic iron ions in hemoglobin. Normal erythrocyte contains approximately 270 million of 
hemoglobin biomolecules and there are four heme groups in each molecule. Hemoglobin 
occupies about a third of the total cell. 98% of the oxygen transported to other body tissue by 
binding with hemoglobin and the remaining about 2% oxygen dissolved in the blood plasma and 
carried to the tissue. The erythrocytes of average adult human contain about 2.5 grams of iron 
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which is about 65% of the total iron stores of contained in the body (McLaren, Brittenham et al. 
1987) 
4.2. Erythropoiesis 
 
                      Figure 1.  Erythropoiesis (Bron, Meuleman et al. 2001). 
The process by which erythrocytes are generated in the body is known as erythropoiesis (Figure 
1). The whole process of development from precursor stem cells to mature erythrocytes comprises 
of about 7 days. It is induced by decreased O2 in circulation, at that point which the kidneys 
secrete erythropoietin. This hormone mediates proliferation and differentiation of red cell 
precursors, which results in activation of erythropoiesis in the hemopoietic tissues. In 
mammals (including humans), erythrocyte production usually occurs within the bone marrow but 
there are a few exceptions. In early fetal life, erythropoiesis takes place in the mesodermal cells of 
the yolk sac. In third or fourth month, spleen and liver are responsible for erythropoiesis (Palis 
and Segel 1998). After seven months, erythropoiesis starts normally in the bone marrow. Mature 
cells circulate for about 100 to 120 days in the body. At the end of their life span, the old 
erythrocyte undergoes some structural changes in its plasma membrane, which make it 
susceptible for macrophages and subsequently phagocytosis in the reticuloendothelial system 
(Foller, Huber et al. 2008). Adopting this way, the old and defective cells are continually removed 
from the blood without hemolysis. 
4.3. Anemia 
Anemia is a pathological condition in which, there is less number of healthy red blood cells or 
less quantity of hemoglobin than normal in blood (Walters and Abelson 1996). However, it can 
include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack 
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in numerical development. Hemoglobin normally carries oxygen from the lungs to the capillaries, 
anemia may leads to hypoxia in organs. As all human cells need oxygen for proper function, 
varying degrees of anemia may leads to wide range of clinical consequences. 
Anemia is one of the most common disorders of the blood. Classification of anemia can be done 
by variety of approaches. On the basis of severity, Anemia may be mild, moderate or severe. In 
mild anemia, hemoglobin ranges from 9.5 to11 g/dl. Mild anemia is asymptomatic condition. In 
moderate anemia, hemoglobin ranges from 8 to 9.5 g/dl, may present with other symptoms but 
need proper management to prevent complications. In severe anemia, hemoglobin concentration 
is always less than 8 g/dl. This is symptomatic and need prompt attention to avoid sever 
complications. Anemia can be life threatening, depends upon the causes and magnitude of the 
RBC and hemoglobin deficiency (Segel, Hirsh et al. 2002). 
On the bases of erythrocytic morphology, anemia can be classified as macrocytic (MCV ˃100), 
normocytic (MCV=100) and microcytic (MCV˂80). The bases for etiological classification of 
anemia include hemorrhage, hemolysis and defective erythropoiesis. Most common symptoms of 
anemia include weakness, fatigue, malaise, poor concentration, pale skin, shortness of breath, 
dizziness and restless legs syndrome. 
To remain functional in blood stream, erythrocytes size and shape should be maintained. 
Erythrocyte with abnormal shapes like spherocytes or elliptocytes and abonormal sizes like 
microcytes or macrocytes may not remains active in the bloodstream for the full life span. If 
sufficient premature destruction occurs, then there is a chance of  disturbance between the 
production and destruction of erytrocytes (Salsbury 2001) which may leads to anemia. 
4.4. Erythrocyte membrane composition 
The erythrocyte membrane plays a vital role in the regulation of erythrocyte surface 
deformability, flexibility, adhesion to other cells and immune recognition. These properties are 
completely dependent on the composition of the membrane. 
The erythrocyte membrane is composed of 3 layers, the exterior carbohydrate-rich glycocalyx, 
the lipid bilayer which contains many transmembrane proteins, and a structural network of 
proteins located on the inner surface of the lipid bilayer also membrane skeleton. By mass, half of 
the cell membrane portion in human erythrocytes is proteins. The other half are lipids, 
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namely phospholipids and cholesterol (Yazdanbakhsh, Lomas-Francis et al. 2000). The 
phospholipids are asymmetrically embedded in the bilayer (Steck 1974). The outer side of the 
bilayer contains sphingomyelin, glycolipids and phosphatidylcholine. The inner part contains 
phosphatidylinositol, phosphatidylserine and phosphatidyl-ethanolamine. (Smith 1987, Palek 
1993). 
The red cell membrane skeleton is a group of protein complexes formed by structural proteins 
including α and β spectrin, ankyrin, protein 4.1 and actin. The key role  of the proteins is to 
interact  with  the  lipid  bilayer  and also with  transmembrane  proteins to keep the cell 
membrane intact (Tse and Lux 1999). So far, more than fifty erythrocyte membrane proteins have 
been recognized and majority of them related to various blood group antigens. Functionally, some 
of  the important membrane proteins are including  band 3, Glut 1, Kidd antigen protein, 
aquaporin 1, Gardos  channel, Na+-K+-ATPase, Ca2+-ATPase, Na+-K+-2Cl-cotransporter, Na+-K+ 
cotransporter, K+-Cl-cotransporter, Na+-Cl- cotransporter,  ICAM-4  and laminin. 
Additionally, membranous proteins are responsible for the adhesion, deformability, flexibility and 
durability. All mentioned properties enable erythrocytes to squeeze through capillaries up to their 
less than half of the diameter (7-8 µm) and regaining of the discoid shape at the end of circulation 
through capillaries. 
4.5. Ionic transportation in Erythrocyte 
Erythrocytes are different from other body cells as they lack both nucleus and mitochondria. 
Erythrocyte further contains an iron containing protein called hemoglobin. This protein has a vital 
role in the balance of ionic environment of the cell by oxygen and carbon dioxide transport and 
pH maintenance in the blood. Additionally,  it has  role  in  the  vasodilatation  of arterioles due to 
binding affinity with nitric oxide (Bessis and Delpech 1981). As shown in the  figure 2, ionic  
transportation  in erythrocytes mainly done by Ca2+-ATPase, Na+-K+-ATPase, Gardos channel, 
K+/Cl−co-transport, Band 3 anion exchanger Na+/K+/2Cl co-transporter and glucose transporter 
(Maher and Kuchel 2003)  
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Figure 2. Ion transportation mechanism in the erythrocyte membrane (Maher and Kuchel 2003). 
The Ca2+-ATP-ase proteins in erythrocyte are responsible for movement of cytosolic Ca2+ from 
intra to the extra-cellular space, mainly for the regulation of signaling inside the cell. Signaling by 
these transmembrane proteins has key role in the apoptosis of erythrocytes. Any defective or 
inhibition of the  Ca2+-ATPase develops high cytosolic Ca2+ concentration and could cause 
apoptosis of erythrocytes also known as eryptosis (Lang, Huber et al. 2007). 
The transmembrane Na+/K+-ATP-ase channels of erythrocytes involved in the regulation of the 
Na+ and K+ concentrations inside the erythrocyte. It is ATP-dependent pump. Normal Na+, K+ 
flux ratio maintain by this pump in erythrocytes is 3:2 (Lew and Bookchin 2005).   
Gardos channels are Ca2+ sensitive K+ channels in erythrocytes. These channels play a vital role 
in the regulation of suicidal erythrocyte death (Lang, Kaiser et al. 2003, Ghashghaeinia, 
Cluitmans et al. 2012). About 100-200 Gardos channels are located on red blood cell membrane 
(Lew, Muallem et al. 1982, Alvarez and Garcia-Sancho 1987). Gardos channels remain inactive, 
at 20-50nM and activates at 150 nM-2 µM Ca2+concentration (Lew and Bookchin 2005). The 
principal out come of the activation of Gardos channels is the release of K+ and Cl- from the cell. 
There is parallel loss of water which leads to erythrocyte shrinkage (Foller, Huber et al. 2008). 
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KCl cotranspoters and Band3 (AE1) proteins are abundant and highly active in precursor’s cells 
of erythrocytes. In reticulocytes, the passive K+ fluxes of are regulated by the KCl cotranspoter 
(Hall and Ellory 1986). In developing erythroblasts, Band3 (AE1) plays a major role as an 
integral protein for the assembly of the membrane skeleton (Peters, Shivdasani et al. 1996). 
4.6. Apoptosis 
Apoptosis is the term alternatively used for programmed or suicidal cell death, characterized by 
morphological changes and mediated by energy-based biochemical mechanisms (Elmore 2007). 
The term apoptosis was used for the first time by Kerr, Wyllie, and Currie in 1972, although 
various components of the programmed erythrocyte death had been described many years before 
(Paweletz 2001, Kerr 2002). In comparison to apoptosis, necrosis is a kind of traumatic cell death, 
generally because of acute cellular injury. Physiologically, apoptosis is recognized as a 
homeostatic mechanism during development and aging stages, mainly to maintain the normal 
populations of cell in tissues. Similarly, it acts as a defense mechanism in the body (Norbury and 
Hickson 2001). 
The morphological changes occurs during apoptosis includes membrane blebbing, cell 
shrinkage, nuclear fragmentation, chromatin condensation and DNA fragmentation. At the end 
apoptotic cell bodies are phagocytosed by macrophages without any inflammatory process (Savill 
and Fadok 2000, Kurosaka, Takahashi et al. 2003). 
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Figure 3.Mechanisms of apoptosis (Zhang, Hartig et al. 2005) 
There are two main apoptotic pathways, the extrinsic or death receptor pathway and the intrinsic 
or mitochondrial pathway (Figure 3). Both pathways are linked together (Igney and Krammer 
2002). Perforin/granzyme pathway recognized as an additional pathway, involving T-cell-
mediated cytotoxicity and perforin-granzyme-dependent suicidal death of cell (Elmore 2007). The 
cytotoxic T lymphocytes (CTLs) kill antigen bearing cells via the extrinsic pathway. The 
FasL/FasR interaction is the key way of CTL mediated apoptosis (Brunner, Wasem et al. 2003). 
All pathways finally converge on an execution phase. 
In extrinsic pathway, death receptors from tumor necrosis factor (TNF) receptor family are the 
key players (Locksley, Killeen et al. 2001). These receptors have cyteine-rich extracellular 
domains with a cytoplasmic domain that is comprises of 80 amino acids known as death domain 
(Ashkenazi and Dixit 1998). This death domain has a vital contribution in the transmission of the 
signal from the surface of the cell to the intracellular signaling pathways. In extrinsic pathway, 
the recognized ligands and their corresponding death receptors are TNF-α/TNFR1, FasL/FasR, 
Apo3L/DR3, Apo2L/ DR4 and Apo2L/DR5 (Suliman, Lam et al. 2001, Rubio-Moscardo, Blesa 
et al. 2005). 
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In contrast, the intrinsic pathways initiate apoptosis by non-receptor-mediated stimuli. The 
intracellular signals directly act on mitochondria and cause changes in the inner membrane. The 
consequences of this phenomenon includes, opening of the mitochondrial permeability transition 
(MPT) pore, loss of transmembrane potential and release two groups of intermembrane pro-
apoptotic proteins (Saelens, Festjens et al. 2004). The first group proteins are, cytochrome c, 
Smac/DIABLO and the serine protease HtrA2/Omi (Garrido, Galluzzi et al. 2006). These proteins 
form an apoptosome by activating caspase-dependent mitochondrial pathway. The second group 
of pro-apoptotic proteins comprises of AIF, endonuclease G and CAD. These are released by 
mitochondria at late stage of apoptosis. AIF causes DNA fragmentation and condensation of 
nuclear chromatin (Joza, Susin et al. 2001). All these apoptotic mitochondrial events are regulated 
by Bcl-2 proteins family (Cory and Adams 2002).  
4.7. Eryptosis 
Eryptosis is the suicidal death of erythrocytes. Aged erythrocytes undergo senescence which 
results in their clearance from the body. Physiologically, eryptosis limits the erythrocyte life span 
to approximately 100–120 days. Events take places for erythrocyte senescence includes, 
attachment of hemichromes to band 3, cluster formation  of band 3 and  deposition  of  C3 
complement fragments  and  anti-band 3 immunoglobulins (Lang and Qadri 2012). 
Programmed cell death has a vital role in the removal of abundant, damaged or potentially 
harmful cells (Gulbins, Jekle et al. 2000). Similar to nucleated cells, erythrocytes are cleared from 
the circulation by suicidal death. As shown in the figure. 4, the macrophages speedily engulf and 
destroy phosphatidylserine exposing cells (Boas, Forman et al. 1998). 
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Figure 4. Phagocytosis of phosphatidylserine exposing erythrocyte by a Kupffer cell in rat liver (Lang, 
Lang et al. 2005) 
Structurally, erythrocytes are deficient of important organelles like nuclei and mitochondria, 
which are considered as key players in apoptosis. Due to this, erythrocytes lack events of 
apoptosis like mitochondrial depolarization, nuclear condensation and DNA fragmentation. 
However, eryptosis possesses similar features of apoptosis including  loss of cellular K+ along 
with cell shrinkage, membrane blebbing and translocation of phosphatidylserine in the plasma 
membrane (Bortner and Cidlowski 1999). 
Due to structural differences, aged erythrocytes eliminated from the circulation by different 
mechanisms in comparison to apoptosis of nucleated cells. Ca2+ is most important element in the 
execution of eryptosis. Incubation of erythrocytes with the Ca2+ ionophore ionomycin bring 
changes like cell shrinkage, membrane blebbing and phosphatidylserine exposure in the cell 
(Berg, Engels et al. 2001).  The cell shrinkage is due to loss of KCl, by the activation of the Ca2+ 
sensitive K+ channels (Lang, Kaiser et al. 2003). Similarly, phospholipid scrambling of the cell 
membrane, may be because of activation of a  Ca2+ sensitive  scramblase (Dekkers, Comfurius et 
al. 2002), inhibition of Ca2+ sensitive and ATP-dependent phospholipid translocase (Seigneuret 
and Devaux 1984). Due to some similarities as well as differences from apoptosis, the term 
eryptosis alternatively used to represent suicidal death of erythrocytes.  
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4.7.1. Signaling pathways of eryptosis 
Ion channels of cellular membrane play a vital role in the erythrocyte suicidal death (Lang, Huber 
et al. 2007). Ca2+-permeable cation channels and Ca2+ sensitive K+ channels (Gardos channels) 
are key player in signaling of eryptosis. 
High cytosolic Ca2+ concentration could be the main cause of eryptosis (Figure 5) and may lead to 
cell membrane scrambling and phosphatidylserine exposure (Akel, Hermle et al. 2006, Nicolay, 
Schneider et al. 2006). Further, Ca2+ entry triggers an endopeptidase calpain, which facilitates  
cell  membrane  blebbing by degradation of the erythrocyte cytoskeleton (Pant, Virmani et al. 
1983). Nonselective cation channels are responsible Ca2+ transport to the cytosol (Kaestner and 
Bernhardt 2002, Lang, Kempe et al. 2005). The activation of these channels is principally 
triggered by osmotic shock (Huber, Gamper et al. 2001), oxidative stress (Duranton, Huber et al. 
2002)  and Cl- removal (Lang, Kempe et al. 2005) 
Another important effect of high erythrocyte cytosolic Ca2+ is the stimulation of Ca2+ -sensitive 
K+ channels. (Bookchin, Ortiz et al. 1987). (Figure 5). Activation of Ca2+-sensitive K+ channels 
leads to the Cl- removal along with K+ (Lang, Warskulat et al. 2003). The loss of KCl parallel 
with water from the cell causes erythrocyte cell shrinkage (Lang, Warskulat et al. 2003).  
               
                      Figure 5. Cation channel regulation in eryptosis (Lang, Lang et al. 2005) 
Ceramide is an important factor to enhance the Ca2+ sensitivity of cellular membrane scrambling, 
similar to elevated intracellular Ca2+ levels which elicits phosphatidylserine translocation in the 
membrane (Lang, Myssina et al. 2004). Ceramide formation is under controlled by platelet 
activating factor. PAF triggers sphingomyelinase, which facilitate sphingomyelin breakdown 
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(Figure 6) (Lang, Kempe et al. 2005). PAF-mediated eryptosis is considered as Ca2+-independent 
eryptosis, as high Ca2+ concentration does not compulsory for PAF activation (Lang, Kempe et al. 
2005). Further, PAF sensitize Ca2+-sensitive K+ channels to stimulate the effects of intracellular 
Ca2+ (Rivera, Jarolim et al. 2002).  
                     
 Figure 6. Regulation of sphingomyelinase in eryptosis (Lang, Lang et al. 2005) 
Energy-depleted environment is among the stimulators of eryptosis. Figure 7 shows the 
mechanism involved in eryptosis induced by energy depletion which is due to the activation of 
protein kinase C (PKC) and PKC-dependent phosphorylation of cytoskeletal proteins (Figure 7) 
(Klarl, Lang et al. 2006). Erythrocytes expresses  PKCa, PKCi, PKCl and PKCf (Govekar and 
Zingde 2001). PKC activation leads to triggering of Ca2+ entry (Andrews, Yang et al. 2002), 
phosphatidylserine exposure (de Jong, Rettig et al. 2002). 
Oxidative stress or defective in anti-oxidative defense (Bilmen, Aksu et al. 2001) stimulate 
eryptosis by facilitating Ca2+ entry through the activation of the Ca2+-permeable cation channels 
(Duranton, Huber et al. 2002). Ca2+-permeable cation channels activity leads to erythrocyte 
shrinkage and thus become the source of induction of eryptosis (Myssina, Lang et al. 2004). 
Figure 7 gives diagrammatic description of the mechanism involved in eryptosis triggered by 
oxidative stress. Oxidative stress mediated suicidal erythrocyte death is paralleled by the 
activation of aspartyl and cysteinyl proteases (Mandal, Baudin-Creuza et al. 2003). During 
oxidative stress, erythrocytes expressed caspases (Bratosin, Estaquier et al. 2001), which leads to 
the cleavage of the anion exchanger band 3 (Mandal, Baudin-Creuza et al. 2003). All events 
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results in the induction of phosphatidylserine translocation in the membrane (Mandal, Moitra et 
al. 2002). 
Hyper osmotic shock-induced eryptosis is mediated by two clear signaling mechanisms (Figure 
7). In the first mechanism, there is an activation of cyclooxygenase (COX), which leads to the 
release of prostaglandin E2 (Lang, Kempe et al. 2005). PGE2 activates Ca2+ permeable cation 
channels (Kaestner and Bernhardt 2002), subsequently increases the intracellular Ca2+ activity 
and phosphatidylserine exposure on the erythrocyte membrane (Kaestner, Tabellion et al. 2004). 
Secondly, osmotic shock turns on phospholipase A2, which regulates the release of platelet 
activating factor. PAF triggers ceramide production by activation of sphingomyelinase in 
erythrocytes (Lang, Kempe et al. 2005).   
 
  
              Figure 7. Summary of suicidal erythrocyte death signaling (Lion, Crettaz et al. 2010). 
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4.7.2. Eryptosis inducers  
Eryptosis may be speedup by stress conditions like osmotic shock (Lang, Duranton et al. 2003), 
oxidative stress and energy depletion (Lang, Roll et al. 2002). Some other inducers of eryptosis 
includes aluminium, amantadine, amiodarone, amphotericin B, amyloid, anandamide, anti-A IgG, 
arsenic, azathioprine, bay 11-7082, bay-Y5884, beauvericin, bismuth chloride, cadmium, 
ceramide (acylsphingosine), chlorpromazine, ciglitazone, cisplatin, copper, cordycepin, curcumin, 
cyclosporine, CD95/Fas/ligand ,dimethylfumarate, FTY720, glycophorin-C, gold salts, hemin, 
hemolysin, IPA3, lead, leukotriene C, lipopeptides, listeriolysin, lithium, mercury, methyldopa, 
methylglyoxal, monensin, paclitaxel, PAF, parthenolide, peptidoglycan, phytic acid, 
prostaglandin E 2 , radio contrast agent, retinoic acid, selenium, silver ions, thrombospondin-1, 
receptor CD47, thymoquinone, tin, valinomycin, sodium vanadate, sphingosine, vitamin K(3), 
zinc (Lang and Qadri 2012) 
4.7.3. Diseases associated with enhanced eryptosis 
Suicidal erythrocyte death is an important feature of many diseases. The diseases showing 
eryptosis are Iron deficiency phosphate depletion, neocytolysis, sepsis, hemolytic anemia, 
hemolytic uremic syndrome, renal insufficiency, diabetes, malaria, sickle-cell disease, 
thalassemia, G6PD deficiency, Wilson’s disease, AE1 mutation, GLUT1 mutation, paroxysmal 
nocturnal hemoglobinuria, myelodysplastic syndrome, hereditary spherocytosis, mycoplasma 
infection, hyperthermia (Lang and Qadri 2012). 
The mouse models with sickle cell anemia, thalassemia, annexin A7 deficiency, cGKI deficiency, 
AMPK deficiency, Endothelin B receptor deficiency, AE1 deficiency, APC deficiency, Klotho 
deficiency, EPO excess has increasing eryptosis tendency (Lang and Qadri 2012). 
4.7.4. Inhibitors of eryptosis 
Certain drugs and natural products are reported as an inhibitor for suicidal death of erythrocytes 
or eryptosis. The important inhibitors for eryptosis are adenosine, amitriptyline, blebbistatin, 
caffeine, catecholamines (isoproterenol), chloride, EIPA, endothelin 1, EPO, flufenamic acid, 
NBQX/CNQX, niflumic acid, NO (nitroprusside), NPPB, phlorhizin, resveratrol, sarafotoxin 6c, 
staurosporine, thymol, urea, WHI-P131/JANEX-1, WHI-P154, xanthohumol, zidovudine.(Lang 
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and Qadri 2012). The mouse model with reduce eryptosis are PDK1 deficiency,TRPC6 
deficiency, PAF receptor deficiency, JAK3 deficiency (Lang and Qadri 2012) 
4.7.5. Consequences related to eryptosis  
Suicidal erythrocyte death is a physiological process but excessive eryptosis due to stress, 
toxicity, diseases or defective compensatory mechanism may leads to anemia. Excessive 
hemolysis due to cell swelling can be prevented, as phosphatidylserine exposure at the cell 
surface of injured erythrocyte is recognized by macrophages, which facilitate clearance of 
erythrocytes from the circulation prior to hemolysis. Further, the activation of Ca2+ sensitive K+ 
channels resist swelling and disruption of damaged erythrocytes, thus increased the time for 
macrophages to clear the injured erythrocytes from the blood. 
The growth of malaria pathogen Plasmodium falciparum can be prevented by rapid clearance of 
infected erythrocytes. The pathogen induces oxidative stress, which facilitate Ca2+ entry by the 
activation of Ca2+- sensitive cation channels and induce eryptosis. The whole mechanism leads to 
the removal of the eryptotic erythrocytes by macrophages. Eventually, reduces the life span of the 
infected cells along with parasites (Lang, Lang et al. 2004). 
Eryptotic erythrocytes have tendency to adhere with the endothelial cells of vascular wall and 
cause blockage in microcirculation (Lang, Gulbins et al. 2010). Due to excessive eryptosis and 
subsequent adherence, the stoppage in the microcirculation of kidney medulla may leads to acute 
renal failure (Abed, Balasaheb et al. 2013). 
4.8. Xenobiotics 
The term xenobiotics is frequently used for chemical compounds which are found in living 
organism, but normally these compounds are not produced and are not expected to be found  in 
that organism. Most of the drugs are xenobiotics, as these are neither produced naturally, nor are a 
part of a normal diet. In other ways, xenobiotics are those substances which are found in higher 
concentration than normal or the artificial substances that are synthetically produced by living 
organism.  
Xenobiotics may be either exogenous or endogenous. The exogenous xenobiotics are compound 
which are neither normally ingested nor utilized. They get entry therapeutically or by food 
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ingestion. The examples of exogenous xenobiotics are drugs, food additives, pollutants, toxins, 
phytochemicals, insecticide and chemical carcinogens. Endogenous xenobiotics are not foreign 
compounds as they are produced in the body as a metabolite in certain processes. The examples 
of endogenous xenobiotics are bile acids, billirubin, steroids, eicosanoid and some fatty acids. 
Pharmaceutically, xenobiotics are very important. It is reported that among all newly approved 
drugs in past year about 40% of the newly approved drugs are either natural products or their 
derivatives and analogues (Cragg, Newman et al. 1997, Tietze, Bell et al. 2003). 
The body removes xenobiotics by metabolism in the liver. This process comprises of the 
deactivation and the excretion. The routes for the excretion of xenobiotics are urine, feces, breath, 
and sweat. A group of liver enzymes like microsomal cytochrome P450 are responsible for the 
metabolism of xenobiotics. Enzyme activate xenobiotics metabolism by different ways like 
oxidation, reduction, hydrolysis or hydration. After that the secondary metabolite bind with 
glucuronic acid or glutathione and subsequently excreted in bile or urine. 
4.9. Mycotoxins 
Mycotoxins are toxic secondary metabolites produced by an organism from the kingdom fungi, 
also known as moulds (Richard 2007).  Fungi are recognized source of several novel natural 
products. Many of these compounds are toxic but in low concentrations. They were shown to 
possess remarkable biological activities, so used as therapeutics in human or veterinary medicine 
(Firakova, Proksa et al. 2007). Mycotoxins are toxic chemicals produced by fungi that normally 
inhabit in food crops (Turner, Subrahmanyam et al. 2009). One type of mould can produce 
chemically different mycotoxin, but one mycotoxin may be produced by other fungal species 
(Robbins, Swenson et al. 2000). Some of the important mycotoxins includes aflatoxins,, 
ochratoxin A, citranin, patulin and toxins from fusarium species. 
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4.9.1. Enniatin A 
 
                        Figure 8. Chemical structure of enniatins (Meca, Giri et al. 2012). 
 
Enniatins are cyclic hexadepsipeptide antibiotics (Dornetshuber, Heffeter et al. 2007). 
Enniatins belongs to a class of organic chemical compounds produced by fusarium species 
(Firakova, Proksa et al. 2007). While working with antibiotic-producing fungi, Gaumann 
discovered some fungal metabolites that were named as enniatin (Burmeister and Plattner 1987). 
Fusarium strains which are responsible for production of enniatins were isolated from different 
sources like walnut tree leaves (Bergendorff, Anke et al. 1994), marine algae Codium fragile 
(Jiang, Barret et al. 2002), foliage of balsam fir Abies balsamea (Strongman, Strunz et al. 1988). 
These fungal toxins also produced by strains of some species of Verticillium (Nilanonta, Isaka et 
al. 2003) and Halosarpheia (Lin, Wang et al. 2002). 
Enniatin biosynthesis is carried out by compounds like l-valine, l-leucine or l-isoleucine, d-2-
hydroxy-3-methylbutanoic, d-2,3-dihydroxy-3-methylpentanoic and d-2-hydroxy- 3-
methylpentanoic acids, ATP, and S-adenosylmethionine (Firakova, Proksa et al. 2007). The 
structural variants of enniatin are enniatin A, A1, B and B1 with minor concentrations of enniatin 
C, D, E and F. The production of enniatins is catalysed by enniatin synthetase, which was purified 
from Fusarium scirpi, F. oxysporum, F. lateritium and F. sambucinum (Zocher, Keller et al. 
1982, Pieper, Kleinkauf et al. 1992). Enniatin synthetase works as constitutive enzyme in primary 
metabolism and it does not regulated by transcriptional or a translational level (Billich and Zocher 
1988). 
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Enniatins as an ionophore are very much interesting for membrane researchers as they have some 
common properties like cyclo-octadepsipeptide valinomycin (MacDonald 1969). Biochemically, 
enniatins are lipophilic ionophores which are incorporated into the cell membrane and forming 
cation selective pores and transmembrane spanning (Firakova, Proksa et al. 2007) 
Enniatins are common contaminants for grain-based food and feed (Behm, Degen et al. 2009, 
Watjen, Debbab et al. 2009). F. avenaceum enniatins plays a role during infection process of 
plants as they contribute to the fungal virulence on potato tuber tissue (Herrmann, Zocher et al. 
1996). Several studies shows that enniatins poses potent antimicrobial and antifungal abilities. 
Enniatin A, A1 and B1 showed moderate antimicrobial against Candida albicans, Cryptococcus 
neoformans and Mycobacterium intracellulare (Jayasinghe, Abbas et al. 2006). At non-toxic 
concentration, enniatins are proved to inhibit the effects of drug efflux pump, which cause 
multidrug resinstance also in cancer cells (Firakova, Proksa et al. 2007). Enniatins have strong 
hypolipidemic activity as in HepG2 cell line enniatin B was shown to inhibit ACAT activity, 
triglyceride biosynthesis and diminished cellular free fatty acids pool (Trenin, Tolstykh et al. 
2000). 
Due to of their apoptotic effects, enniatins are listed together with strong anticancer agents of 
natural origin (Watjen, Debbab et al. 2009). Enniatins have cytotoxic capabilities (Hyun, Lee et 
al. 2009), potentially able to cause cell cycle arrest (Dornetshuber, Heffeter et al. 2007) and 
induce apoptosis in mammalian cells (Dornetshuber, Heffeter et al. 2007, Behm, Degen et al. 
2009, Tonshin, Teplova et al. 2010). Mixture of enniatins O1, O2, O3 proved cytotoxic against 
cancer cell lines KB,BC-1 and NCI-185 (Supothina, Isaka et al. 2004). Enniatins were tested in 
vivo for their anti-HIV activity (McKee, Bokesch et al. 1997). Enniatins do not exert oxidative 
stress or cause DNA damage (Behm, Degen et al. 2009). Their cytotoxic effects are mainly due to 
the damage of mitochondrial transmembrane potential, uncoupled oxidative phosphorylation, 
swelling of mitochondria and decreasing of mitochondrial ability to sequester Ca2+. 
(Dornetshuber, Heffeter et al. 2007). Enniatins are recognized as potentially selective K+ 
ionophores in cellular membranes (Tonshin, Teplova et al. 2010). The apoptotic death induced by 
enniatins is caspase-dependent and is inhibited by the pancaspase inhibitor zVAD (Hyun, Lee et 
al. 2009). Further, enniatin were shown to involve in the inhibition of extracellular regulated 
protein kinase (ERK) as well as in the down regulation of NF-kB (Watjen, Debbab et al. 2009). 
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4.9.2. Ochratoxin A 
 
 
                     Figure 9. Chemical structure of ochratoxin A (Tafuri, Ferracane et al. 2004). 
Ochratoxin A (OTA) is a toxic fungal metabolite, produced by several subspecies of the 
genera Penicillium and Aspergillus (Zhang, Boesch-Saadatmandi et al. 2009). OTA found in 
foods with plant origin, edible animal tissues, human blood and tissues (Kuiper-Goodman and 
Scott 1989). Chemical structure in the figure 9 is showing that ochratoxin A is a pentaketide 
derived from the dihydrocoumarins family coupled to β-phenylalanine. Its chemical name is: L-
phenylalanine -N- [(5-chloro-3,4-dihydro-8-hydroxy-3-methyl-1-oxo-1H-2-benzopyrane-7-yl) 
carbonyl] (R)isocoumarin. Several metabolites related to ochratoxin A have been discovered 
recently. Among all, its dechloro analog Ochratoxin B (OTB), its ethyl ester ochratoxin C (OTC), 
its isocoumaric derivative Ochratoxin α (Otα) and its dechloro analog, ochratoxin β (OTβ) are 
famous.(el Khoury and Atoui 2010) 
Ochratoxin A is known to have great health and agricultural significance. (Coronel, Sanchis et al. 
2010, Duarte, Pena et al. 2011). In eastern Euorpe, the highest detected quantity of OTA in food 
of plant origin was about 5410 lg/kg in rye flour of Poland and 3800 lg/kg in barley of 
Czechoslovakia (Speijers and Vanegmond 1993). OTA proved very toxic to various animal 
species, the kidney being the main affected (Pohland, Nesheim et al. 1992). Some other effects 
related to OTA toxicity in animals includes cardiac and hepatic histological abnormalities, 
hemorrhage and thrombosis in the spleen, brain, liver, kidney and heart due to aberration of 
coagulation factors in rats (Albassam, Yong et al. 1987), myelotoxicity in mice (Boorman, Hong 
et al. 1984, Muller, Kielstein et al. 1995), gastro-intestinal tract and lymphoid tissues lesions in 
the hamster (Hagelberg, Hult et al. 1989), intestinal fragility and lesions of the kidney in chickens 
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(Elling, Hald et al. 1975), decreased feed intake in chickens after OTA exposure in feed (Prior, 
O'Neil et al. 1980). After mixing 2 ppm OTA in poultry feed, signs of ochratoxicosis including 
weight loss, low egg production, high water intake, diarrhea, excessive urination (Prior and 
Sisodia 1978) and hematological modifications (Bailey, Gibson et al. 1989) were noted. OTA has 
been known to inhibit protein synthesis in bacteria, yeast and mammalian cells in vitro and 
animals in vivo (Dirheimer and Creppy 1991). 
As far as human health is concerned, ochratoxin A proved very toxic for organs such as kidney, 
liver, stomach, intestine, neurons, and immune cells (Zhang, Boesch-Saadatmandi et al. 2009, 
Duarte, Lino et al. 2011). Moreover, OTA has teratogenic potential (el Khoury and Atoui 2010). 
It is famous as a causative agent of Balkan endemic nephropathy and may contribute to the cause 
of urinary tract tumors (Mally and Dekant 2009, el Khoury and Atoui 2010). In renal epithelial 
cells, OTA activates the mitogen activated protein kinases ERK, JNK and p38. Activation of 
ERK results in mitosis, growth and differentiation, while JNK and p38 activation brings opposite 
effects (Sauvant, Holzinger et al. 2003). The nephrotoxicity of OTA may be due to mitochondrial 
dysfunction bringing to energy shortage and to the reactive oxygen species production. The 
treatment of isolated renal proximal tubules with OTA cause inhibition of mitochondrial 
respiration (Aleo, Wyatt et al. 1991). OTA also showed a powerful immunosuppressant effect at 
low or high doses as necroses of lymphoid tissues were observed after OTA treatment (Creppy, 
Betbeder et al. 1991).Humoral and cellular immunity were also compromised after OTA exposure 
(Holmberg, Thuvander et al. 1988). Further, OTA toxicity may cause iron deficiency anemia 
(Huff, Chang et al. 1979, Stoev, Anguelov et al. 2000).  
Oxidative stress is a potential cause of toxicity and carcinogenicity induced by OTA as an 
elevated formation of the lipid peroxidation product malondialdehyde (MDA) was found in rats 
treated orally with 120 mg/kg bw/day of OTA for more than 60 days  (Petrik, Zanic-Grubisic et 
al. 2003). Along with toxicity, OTA  proved very effective as an inducer of suicidal death in 
many types of cell (Bouaziz, Sharaf El Dein et al. 2008, Ranaldi, Caprini et al. 2009, Yoon, Cong 
et al. 2009, Zhang, Boesch-Saadatmandi et al. 2009, Chopra, Link et al. 2010, Cui, Xing et al. 
2010). Mechanisms involved in the triggering of suicidal death of cells by OTA  include oxidative 
stress (El Golli Bennour, Rodriguez-Enfedaque et al. 2009, Yenilmez, Isikli et al. 2010), JNK and 
p38 pathways  (Gekle, Sauvant et al. 2005, Sauvant, Holzinger et al. 2005) and Ca2+ entry into the 
cell (Klaric, Zeljezic et al. 2012). 
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4.9.3 Zearalenone 
 
 
               Figure 9. Chemical structure of zearalenone (Gromadzka, Waskiewicz et al. 2009). 
Zearalenone (ZEA; previously named as F-2 toxin) is a non-steroidal oestrogenic mycotoxin 
produced by a variety of Fusarium fungi, including F. graminearum (Gibberella zeae), F. 
culmorum, F. cerealis, F. equiseti, F. crookwellense and F. semitectum, which are common soil 
fungi and are worldwide famous cereal crops contaminants (Bennett and Klich 2003). Figure 9 
depicts that, biochemically ZEA is a resorcyclic acid lactone (6-(10-hydroxy-6-oxo-trans-1-
undecenyl)-B-resorcyclic acid lactone) (Zinedine, Soriano et al. 2007). The favorable conditions 
for ZEA production is high humidity and low temperature (Caldwell, Tuite et al. 1970). ZEA 
found as a very stable compound as it does not degraded at high temperature. (Kuiper-Goodman, 
Scott et al. 1987). 
Fungi responsible for the production of ZEA and its metabolites mainly colonize in corn and to a 
lesser extent in barley, oats, wheat, sorghum, millet and rice. Additionally, ZEA also found in 
some cereal based products like flour, malt, soybeans and beer. (Zinedine, Soriano et al. 2007). 
ZEA derivatives like α-zearalenol, β-zearalenol, α-zearalanol, β-zearalanol and zearalanone found 
in Fusarium infected corn (Bottalico, Visconti et al. 1985)  and in rice  (Richardson, Hagler et al. 
1985). In comparison, α- zearalenol proved  three times more estrogenic than β-zearalenol 
(Hagler, Mirocha et al. 1979). Animals studies showed that zearalenone metabolites alpha-
zearalenol (alpha-ZEA) and beta-zearalenol (beta-ZEA) are produced by the biotransformation 
and subsequently conjugated with glucuronic acid (Zinedine, Soriano et al. 2007) therefore, the 
dietary intake of ZEA from meat and products has less significance (Creppy 2002).  
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The toxicity cause by ZEA and its metabolites may be acute, sub acute or chronic and the 
outcomes are reproductive defects, developmental abnormalities, carcinogenicity, genotoxicity 
and immunotoxicity (Zinedine, Soriano et al. 2007). Zearalenone and its derivatives affect human 
and animal reproduction by interacting with estrogen receptorsas was shown in vitro. (Yazar and 
Omurtag 2008). The reduced form of a-zearalenol found as an anabolic substance. In post-
menopausal women, it is used for the hormonal replacement and as an oral contraceptive (Pazaiti, 
Kontos et al. 2012). ZEA is also capable to induce  biophasic changes in the luteinizing hormone 
but not the follicle stimulating hormone (Bongiovanni 1983). ZEA exposure may stimulate 
pubertal development (Massart and Saggese 2010). Hematopoietic progenitor cells are also 
effectors of the toxicity of ZEA (Ficheux, Sibiril et al. 2012). Young children after exposure to 
zearalenone showed some precocious pubertal changes, which may be due to ZEA toxicity (Saenz 
de Rodriguez 1984). In bovine lymphocytes, ZEA causes genotoxicity by triggering DNA-adduct 
formation (Lioi, Santoro et al. 2004). 
At lower concentrations, ZEA may have pro-apoptotic effect (Ahamed, Foster et al. 2001) but at 
higher concentrations ZEA is found as a strong apoptotic compound for different kind of  cells 
(Abid-Essefi, Baudrimont et al. 2003, Kim, Son et al. 2003, Minervini, Giannoccaro et al. 2006, 
Doric, Radovic et al. 2007, Kouadio, Dano et al. 2007, Ayed-Boussema, Bouaziz et al. 2008, 
Banjerdpongchai, Kongtawelert et al. 2010, Malovrh and Jakovac-Strajn 2010, Salah-Abbes, 
Abbes et al. 2010, Yu, Zheng et al. 2011). Hyperestrogenism due to ZEA exposure 
triggers apoptosis and decreases the proliferative ability of follicular cells (Gajecka 2013). 
Signaling for the suicidal death induced by zearalenone includes CD95 (Jee, Noh et al. 2010), 
mitogen-activated  protein  kinases  (Yu, Zheng et al. 2011), transcription factor p53 (Ayed-
Boussema, Bouaziz et al. 2008, Yu, Zheng et al. 2011), Bax expression (Bouaziz, Martel et al. 
2009, Banjerdpongchai, Kongtawelert et al. 2010), reactive oxygen species  (Bouaziz, Martel et 
al. 2009, Banjerdpongchai, Kongtawelert et al. 2010, Salah-Abbes, Abbes et al. 2010, Yu, Zheng 
et al. 2011), mitochondrial depolarization (Ayed-Boussema, Bouaziz et al. 2008, Bouaziz, Sharaf 
El Dein et al. 2008, Banjerdpongchai, Kongtawelert et al. 2010, Zhu, Yuan et al. 2012), 
apoptosis-inducing factor (Yu, Zheng et al. 2011), endoplasmic reticulum stress 
(Banjerdpongchai, Kongtawelert et al. 2010), caspase  activation  (Zhu, Yuan et al. 2012) and 
increase  in  intracellular  Ca2+ (Vlata, Porichis et al. 2006).  
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4.10. Phytochemicals 
Phytochemicals are the chemical compounds which are isolated from plants by using highly 
sophisticated biochemical and analytical approaches. Plants are considered as a potent source of 
many drugs such as antispasmodics, emetics, anti-cancer, antimicrobials, and anticoagulants. 
Phytochemicals are non-nutritive constituents of the diet of plant origin, having anticarcinogenic 
and antimutagenic effects (Surh 2003). Some of the important examples of phytochemicals with 
pharmacological properties are vitamins, curcumin, capsaicin, gingerol, epigallocatechin-3-
gallate, genistein, dulphoraphane, indole-3-carbinol, diallyl sulphide, caffeic acid phenethyl ester 
and resveratrol. 
4.10.1. Withaferin A  
 
 
                  Figure 10. Chemical structure of Withaferin A (Debnath, Chattopadhyay et al. 2012). 
Withania somnifera is an Indian medicinal plant, famous as Indian ginseng because of its 
beneficial effects on human health. W. somnifera found mainly in India, Pakistan, Afghanistan, 
Sri Lanka, Congo, South Africa, Egypt, Morocco, and Jordan (Dafni and Yaniv 1994, Kulkarni 
and Dhir 2008). It has anti-inflammatory, antitumor, antistress, antioxidant, immunomodulatory 
and hemopoietic effects. Also has beneficial role for the endocrine, cardiopulmonary, and central 
nervous systems (Mishra, Singh et al. 2000). Withanolides are biologically active compounds 
extracted from W. somnifera, including alkaloids, steroidal lactones, saponins containing an 
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additional acyl group, sitoindosides, flavonoids and tannins (Mishra, Singh et al. 2000, Kuo, Kuo 
et al. 2006, Bandyopadhyay, Jha et al. 2007) 
Withaferin A is a triterpenoid Withanolide from plant Withania somnifera (Mirjalili, Fakhr-
Tabatabaei et al. 2009). Figure 10 depicts withaferin A as 4β, 27-dihydroxy-1-oxo-5β, 6β-
epoxywitha-2-24-dienolide compound. It is a steroidal lactone which binds to vimentin and 
inhibits it (Bargagna-Mohan, Hamza et al. 2007). 
Withaferin A structure gives insight about its cytotoxicity. Fuska and his co worker found that the 
unsaturated A ring of withaferin A was crucial for the cytotoxicity. Withaferin A derivatives with 
dissociated double bond possessed little cytotoxicity while the C27 hydroxyl group and the α , β-
unsaturated δ-lactone ring with double bond at C24-25 were not essential for the cytotoxicity 
indued by withaferin A (Fuska, Fuskova et al. 1984). Further, 4 β -hydroxy-5 β, 6 β -epoxy-2-en-
1-one moiety was crucial for the stimulation of cell differentiation by withaferin A but  α, β -
unsaturated δ -lactone ring was not important for same activity (Kuroyanagi, Shibata et al. 1999), 
similarly, 5β, 6β-epoxide group considered very important for withanalides cytotoxicity (Damu, 
Kuo et al. 2007). 
Withaferin A is anti-inflammatory (Kaileh, Vanden Berghe et al. 2007, Sabina, Chandal et al. 
2008, Maitra, Porter et al. 2009) may be due to  NFκB inhibition (Maitra, Porter et al. 2009), anti-
tumor (Devi, Sharada et al. 1995, Sharada, Solomon et al. 1996), anti-angiogenesis (Mohan, 
Hammers et al. 2004), radio-sensitizing activity (Devi, Kamath et al. 2000), chemopreventive 
(Manoharan, Panjamurthy et al. 2008), and immunosuppressive (Shohat, Kirson et al. 1978). 
Withaferin A has anti tumor effect (Devi 1996, Mirjalili, Fakhr-Tabatabaei et al. 2009). 
Withaferin A may inhibit tumor growth by stimulating apoptosis of nucleated cells (Bargagna-
Mohan, Hamza et al. 2007, Sen, Banerjee et al. 2007, Srinivasan, Ranga et al. 2007, Oh, Lee et al. 
2008, Park, Rayalam et al. 2008, Samadi, Tong et al. 2010, Zhang, Samadi et al. 2012). 
Withaferin A induce apoptosis by several ways, which includes modification of  gene expression 
(Stan, Hahm et al. 2008, Maitra, Porter et al. 2009, Grover, Shandilya et al. 2010, Koduru, Kumar 
et al. 2010, Lee, Hahm et al. 2010, Yu, Hamza et al. 2010, Hahm, Lee et al. 2011, Munagala, 
Kausar et al. 2011), mitochondrial depolarization (Malik, Kumar et al. 2007, Mandal, Dutta et al. 
2008, Mayola, Gallerne et al. 2011, Yang, Choi et al. 2011), oxidative  stress  (Malik, Kumar et 
al. 2007, Hahm, Lee et al. 2011, Mayola, Gallerne et al. 2011, Yang, Choi et al. 2011), induction 
of endoplasmic reticulum stress (Choi, Park et al. 2011), Par-4 induction (Srinivasan, Ranga et al. 
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2007), p38 MAP kinase activation (Mandal, Dutta et al. 2008), inhibition of JAK/STAT3 (Um, 
Min et al. 2012) and FOXO3a- and Bim-dependent apoptosis (Stan, Hahm et al. 2008), inhibit 
protein kinase C (PKC) activity in leishmanial cells (Sen, Banerjee et al. 2007). The signal 
transduction and activation of transcription 3 (STAT3) may be molecular target of withaferin A 
(Lee, Hahm et al. 2010). Withaferin A showed in vivo anticancer activity in pancreatic 
cancer cells by inhibition of Hsp90 via an ATP-independent mechanism, cause Hsp90 client 
protein degradation (Yu, Hamza et al. 2010). 
4.10.2. Oridonin 
 
                                 Figure 11. Chemical structure of oridonin (Lou, Gao et al. 2011) 
Oridonin is an active tetracycline diterpenoid (Figure 11) compound, purified from traditional 
Chinese herb Rabdosia rubescens (Liu, Ouyang et al. 2012) alternatively known as rubesecensin 
A (Du, Villeneuve et al. 2008). Isodon plant Rabdosia rubescens, also famous as Donglingcao. 
The aerial parts of RR and other species from the same genus performed many functions 
including heat, toxicity, nourishment, blood stasis, and relief from swelling. Rabdosia rubescens 
has been used for the treatment of stomach ache, sore throat and cough. Moreover, RR and its 
extracts are capable to control disease progress, reduction in tumor mass and enhanced survival in 
patients suffering from gastric carcinoma, esophageal, liver and prostate cancer (Zhou, Chen et al. 
2007).  
Oridonin was identified for the first time in 1967 from Rabdosia rubescens and subsequently 
synthesized in 1973  (Li, Wang et al. 2011). As far as the stability is concerned, oridonin showed 
high stability in rabbit plasma, as both stock solutions and working solutions were over 99% of 
the nominal concentrations after storage at -20 ◦C for 30 days and 4 ◦C for 7 days (Mei, Xu et al. 
2008). Additionally, oridonin in rat plasma retain its stability at room temperature for 12 h and -
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20 ◦C for 30 days (Du, Liu et al. 2010). In medical applications, oridonin has some limitations as 
a therapeutic substance due to its lower solubility, therefore cytotoxicity of oridonin can be 
increase by adopting new ways for the preparation of oridonin nanosuspension and nanoparticle 
(Lou, Zhang et al. 2009). Production of derivative could be another possibility to enhance the 
cytotoxicity of oridonin. (Xu, Yang et al. 2008).  
Oridonin exhibit potential anti-tumor capability (Gao, Zhang et al. 2008). Oridonin also showed 
therapeutic effectiveness as an immunosuppressive and anti-inflammatory (Hu, Du et al. 2008, 
Xu, Xue et al. 2009) and may be beneficial for the treatment of pulmonary hypertension (Wang, 
Sun et al. 2009). Treatment with cause modification in gene expression, induce of oxidative 
stress, cell  cycle  arrest, senescence, autophagy, apoptosis and phagocytosis of apoptotic cells 
(Hsieh, Wijeratne et al. 2005, Ikezoe, Yang et al. 2005, Hu, Yang et al. 2007, Cheng, Qiu et al. 
2009, Gao, Tang et al. 2010, Gao, Hu et al. 2010).  
Effectiveness against several cancer cells, give identification to oridonin and its derivatives as 
potent anticancer agents (Zhou, Kang et al. 2007, Zhu, Xie et al. 2007, Lou, Zhang et al. 2009, Li, 
Wang et al. 2011). Both In vitro and in vivo studies showed that oridonin possesses anti 
proliferative activity against breast, prostate, non-small cell lung cancer, glioblastoma multiforme 
(Zhang, Wu et al. 2004), human fibrosarcoma (HT1080 cells), human epidermoid carcinoma 
(A431 cells), murine aneuploid fibrosarcoma (L929 cells), human colon carcinoma HT29 cells, 
P388 lymphocytic leukaemia and Ehrlich ascites (Node, Sai et al. 1983, Li, Cui et al. 2007, Zhu, 
Xie et al. 2007, Cheng, Qiu et al. 2008, Zhang, Wu et al. 2009). Oridonin may be useful for the 
treatment of lymphoid malignancies, including adult T-cell leukemia and other types of cancers in 
which NF-κB activation is involved. Similarly, oridonin inhibits NF-κB activity in inflamed 
synovial cells from patients suffering from rheumatoid arthritis. (Ikezoe, Yang et al. 2005). 
Along with autophagy and apoptosis, oridonin has been shown to stimulate G2/M phase cell cycle 
arrest in L929 cells (Cheng, Qiu et al. 2009). It also induce suicidal death and senescence in 
colorectal cancer SW1116 cells in vivo (Gao, Hu et al. 2010). Further, oridonin not only induced 
typical mitochondrial suicidal cell death in acute myeloid leukemic (AML) cells (Chen, Gao et al. 
2005) but in murine models, also showed potential anti-leukemia effect with a low side-effect 
(Zhou, Chen et al. 2007). 
Signaling for apoptosis triggers by oridonin includes, oxidative stress, calpain activity, DNA 
damage, histone (H3 and H4)  hyperacetylation, p38 MAP kinase activation,  p21,  p27,  p16,p53, 
cyclin  B1/p-Cdc2, inhibition of tyrosine kinase activity, PI3 kinase pathway and NFjB, 
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Ras/Raf/ERK signal pathway, suppression of c-myc expression, mitochondrial depolarization and   
cytochrome   c release and caspase activation (Zhang, Wu et al. 2004, Hu, Yang et al. 2007, Li, 
Wu et al. 2008, Cheng, Qiu et al. 2009, Cheng, Qiu et al. 2009, Cho, Moon et al. 2009, Zhang, 
Wu et al. 2009, Feng, Zhang et al. 2011, Gatsinzi and Iverfeldt 2011). At a low sub toxic dosage, 
oridonin protects against arsenic-induced cytoxicity by the activation of Nrf2 signaling pathway 
and was capable to stabilize Nrf2 by the inhibition of Nrf2 ubiquitination and degradation which 
lead to the accumulation of the Nrf2 protein and activation of the Nrf2-dependent cyto protective 
response. (Du, Villeneuve et al. 2008). 
 
4.10.3. Dicoumarol 
  
Figure 12. Biosynthesis of Dicoumarol (Link 1959) 
Natural anticoagulant dicoumarol or 3,3’-methylenebis[4-hydroxycoumarin] (Figure 12) is a 
derivative of coumarin (Madari, Panda et al. 2003). It is metabolized from coumarin in the sweet 
clover like Melilotus alba and Melilotus officinalis by the action of like molds Penicillium 
nigricans and Penicillium jensi. Coumarin (1,2-benzopyrone) is the simple compound from a  
large class of naturally occurring phenolic substances made by fusion of the benzene and α-
pyrone rings (Madari, Panda et al. 2003). Coumarin and its derivatives expressed various 
antitumor and antiproliferative effects. In vitro studies showed that the coumarin compounds 
stops proliferation of human malignant cell lines (Marshall, Mohler et al. 1994, Brar, Kennedy et 
al. 2001). Similarly, in vivo experiments expressed anti tumor activity (Feuer, Kellen et al. 1976, 
Maucher and von Angerer 1994, Madari, Panda et al. 2003). In clinical trials coumarin 
compounds proved anti proliferative against prostate cancer, malignant melanoma and metastatic 
renal cell carcinoma (Marshall, Butler et al. 1991, Mohler, Gomella et al. 1992, Thornes, Daly et 
al. 1994). Additionally, the coumarin anticoagulants, dicoumarol and its synthetic derivative 
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warfarin sodium proved capable to decrease metastases in animal models (Smith, Neubauer et al. 
1988). 
Dicoumarol is also famous as vitamin K antagonist (Stirling 1995, Lotrionte, Castagno et al. 
2009). In humans, dicumarol is slowly metabolized to unknown transformation products. The 
drug is mainly localized on the proteins of plasma and in other body tissues. Dicumarol is slowly 
absorbed from the gastrointestinal tract and there is considerable variation in the absorption rate 
among different individuals. Furthermore, the small doses are absorbed quickly than large and 
similarly, the rate of transformation also depends on the dose as the smaller doses metabolized 
with a faster rate (Weiner, Shapiro et al. 1950). 
Dicuomarol has multiple side effects (Nolan, Scott et al. 2010, Scott, Barnes et al. 2011). One of 
the side effects of dicoumarol treatment is anemia, may be due to excessive bleeding (Drucker-
Colin, Jaques et al. 1971, Runciman, Lee et al. 2002). Dicoumarol proved very effective for the 
treatment of acute arterial occlusions (Petit and Berne 1947). Dicoumarol is not used only to 
increase the prothrombin time of patients but also to prevent thrombosis.(Jaques 1959). It may 
sensitize cells against the cytotoxicity of different chemicals (Watanabe, Nishiyama et al. 2006, 
Cabello, Bair et al. 2009). On the other hand, dicoumarol may accelerate cytotoxicity (Wondrak 
2007, Dong, Bey et al. 2010). It is also proved hepatotoxic as it affects the plasma concentration 
of fibrinogen which is produced in the liver as well as proved toxic for the heart muscles and may 
be cause heart failure. (Jaques 1959). In the liver, dicoumarol presumably inhibits an enzyme 
network. (Martius and Nitz-Litzow 1955). 
Cytotoxicity induced by dicoumarol is not always interfere with vitamin K epoxide 
oxidoreductase or a previously unidentified features of vitamin K metabolism, as the  vitamin K 
addition does not effect the anti proliferation of cells by dicoumarol (Du, Daniels et al. 2006). 
Antiproliferative effects of dicoumarol possibly by stabilizing spindle microtubule dynamics 
through a unique interaction with tubulin and microtubules (Madari, Panda et al. 2003). Inhibition 
of cell growth by dicoumarol may be relatively specific for different tumor cells, since production 
of normal airway myocytes of human origin is not affected (Brar, Kennedy et al. 1999). 
Dicoumarol and other coumarin compounds are as used cancer therapy but mechanism of action 
of these compounds is not so much clear (Du, Daniels et al. 2006). In human pancreatic cancer 
cells dicuomarol triggers cytotoxicity and oxidative stress (Du, Daniels et al. 2006). Dicoumarol 
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induced oxidative stress by intracellular inhibition of NQO1, leads to increased cell toxicity 
(Hosoda, Nakamura et al. 1974, Hollander and Ernster 1975). Studies to find out the cytotoxic 
effects of dicoumarol demonstrate that the mitochondrial metabolism might be part of the 
mechanism (Winski, Koutalos et al. 2002, Lewis, Ough et al. 2005). Dicoumarol induces its 
toxicity on cells by interfering with mitochondrial function and stimulation of superoxide 
production (Bello, Gomez-Diaz et al. 2005, Gonzalez-Aragon, Ariza et al. 2007). In transformed 
fibroblast cell lines, dicoumarol decreased clonogenic survival in IMRSV-90 as compared to 
IMR-90 (Du, Daniels et al. 2006). 
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5. AIM OF THE STUDY 
The prime objectives of the study were to determine the mechanisms and signaling involved in 
the regulation of suicidal erythrocyte death induced by xenobiotics. To rule out the effective 
dosages for the induction of suicidal death and cytotoxicity, erythrocytes were treated with 
different food borne mycotoxins and therapeutically important phytochemicals under their 
reported plasma level. 
In the first section of the study, erythrocytes were treated in vitro with different molar 
concentration of food contaminating mycotoxins enniatin A, ochratoxin A and zearalenone. 
Experiments were performed to measure cytosolic calcium activity, phosphatidylserine exposure 
on cell surface, cell volume changes, and ceramide formation by FACS analysis. To find out 
additional signaling pathways and elaborate the previous findings, further investigations like 
cytosolic ATP levels, hemolysis measurement, adhesion studies and confocal microscopy were 
performed. 
In the second section of the study, in vitro experiments were performed after treatment of 
erythrocytes with different molar concentration of phytochemicals withaferin A, oridonin and 
dicoumarol. Intracellular Ca2+ activity, phosphatidylserine exposure on cell surface, cell volume 
changes, ceramide formation and ROS formation were determined by FACS analysis. To find 
additional signaling mechanisms involved in eryptosis and strengthen our previous observations, 
further experiments like cytosolic ATP concentration, patch clamp recordings, hemolysis 
measurement and confocal microscopy were also performed. 
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6. MATERIAL AND METHODS 
6.1. Stimulation of suicidal death of erythrocytes by mycotoxins 
6.1.1. Erythrocytes, solutions and chemicals 
Leukocyte-depleted erythrocytes (aged 1-2 weeks) were kindly provided by the blood bank of the 
University of Tübingen. Viability of erythrocytes may depend on the donor and the storage time thus 
causing some inter-individual variability. To avoid any bias potentially introduced by the use of 
different erythrocyte batches, comparison was always made within a given erythrocyte batch. The 
study was approved by the ethics committee of the University of Tübingen (184/2003V). 
Erythrocytes were incubated in vitro at a hematocrit of 0.4% in Ringer solution containing (in mM) 
125 NaCl, 5 KCl, 1 MgSO4, 32 N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid (HEPES), 5 
glucose, 1 CaCl2; pH 7.4 at 37°C for 48 hours. Where indicated, extracellular glucose was removed.  
Erythrocytes were exposed to enniatin A (Enzo, Lörrach, Germany), ochratoxin A (Enzo, Lörrach, 
Germany) and Zearlenone (Enzo, Lörrach, Germany), added at the indicated concentrations. In Ca2+-
free Ringer solution, 1 mM CaCl2 was substituted by 1 mM glycol-bis(2-aminoethylether)-
N,N,N',N'-tetraacetic acid (EGTA). Where indicated, the caspase inhibitor zVAD (Enzo, Lörrach, 
Germany) was used at a concentration of 10 µM, the protein kinase C inhibitor staurosporine 
(Sigma, Freiburg, Germany) was used at a concentration of 500 nM and oxidative stress was induced 
utilizing 0.3 mM tert-butyl hydroperoxide [t-BOOH] (Sigma, Freiburg, Germany).   
All incubations (48 hours) were carried out in Ringer solution containing 1 mM CaCl2 or where 
indicated in Ca2+-free Ringer solution. Following preteatment with the respective Ca2+ containing or 
Ca2+ free solutions for the indicated time periods the erythrocytes were washed with Ringer solution 
containing 5 mM CaCl2 and resuspended for 20 minutes with the same solution containing Annexin 
V-Fluos. The time period of 20 minutes is considered too short for the triggering of eryptosis.   
6.1.2. FACS analysis of annexin V-binding and forward scatter  
After incubation under the respective experimental conditions, 50 µl cell suspension were washed in 
Ringer solution containing 5 mM CaCl2 and then stained for 20 minutes with Annexin-V-Fluos 
(1:500 dilution; Roche, Mannheim, Germany) under protection from light [32]. In the following, the 
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forward scatter (FSC) of the cells was determined and annexin V fluorescence intensity was 
measured in FL-1 with an excitation wavelength of 488 nm and an emission wavelength of 530 nm 
on a FACS calibur (BD, Heidelberg, Germany). 
6.1.3. Measurement of intracellular Ca2+ 
After incubation 50 µl suspension erythrocytes were washed in Ringer solution and then loaded with 
Fluo-3/AM (Calbiochem, Bad Soden, Germany) in Ringer solution containing 5 mM CaCl2 and 2 
µM Fluo-3/AM. The cells were incubated at 37°C for 20 min and washed twice in Ringer solution 
containing 5 mM CaCl2. The Fluo-3/AM-loaded erythrocytes were resuspended in 200 µl Ringer. 
Then, Ca2+-dependent fluorescence intensity was measured in fluorescence channel FL-1 in FACS 
analysis. 
6.1.4. Determination of ceramide formation 
For the determination of ceramide, a monoclonal antibody-based assay was used. After incubation 
with and without ochratoxin A, cells were stained for 1 h at 37°C with 1 µg/ml anti-ceramide 
antibody (clone MID 15B4, Alexis, Grünberg, Germany) in PBS containing 0.1% bovine serum 
albumin (BSA) at a dilution of 1:5. The samples were washed twice with PBS-BSA. Subsequently, 
the cells were stained for 30 minutes with polyclonal fluorescein-isothiocyanate (FITC)-conjugated 
goat anti-mouse IgG and IgM specific antibody (Pharmingen, Hamburg, Germany) diluted 1:50 in 
PBS-BSA. Unbound secondary antibody was removed by repeated washing with PBS-BSA. The 
samples were then analyzed by flow cytometric analysis in FL-1.  
6.1.5. Determination of intracellular ATP concentration 
For determination of intracellular ATP, 90 µl of erythrocyte pellets were incubated for 48 h at 37°C 
in Ringer solution with or without enniatin A (final hematocrit 5%). Additionally, erythrocytes were 
also incubated in glucose depleted Ringer solution as a positive control. All manipulations were then 
performed at 4°C to avoid ATP degradation. Cells were lysed in distilled water, and proteins were 
precipitated by addition of HClO4 (5%). After centrifugation, an aliquot of the supernatant (400 µl) 
was adjusted to pH 7.7 by addition of saturated KHCO3 solution. After dilution of the supernatant, 
the ATP concentrations of the aliquots were determined utilizing the luciferin–luciferase assay kit 
(Roche Diagnostics) on a luminometer (Berthold Biolumat LB9500, Bad Wildbad, Germany) 
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according to the manufacturer's protocol. ATP concentrations are expressed in mmol/l cytosol of 
erythrocytes. 
6.1.6. Measurement of hemolysis 
For the determination of hemolysis the samples were centrifuged (3 min at 400 g, room temperature) 
after incubation, and the supernatants were harvested. As a measure of hemolysis, the hemoglobin 
(Hb) concentration of the supernatant was determined photometrically at 405 nm. The absorption of 
the supernatant of erythrocytes lysed in distilled water was defined as 100% hemolysis. 
6.1.7. Cell culture and in vitro adhesion studies 
Human umbilical vein endothelial cells (HUVEC) from early passage of culture were cultured in 
complete endothelial cell basal medium (PAA) containing growth factors and 10% fetal bovine 
serum and grown to confluency. HUVEC (5 × 105) were attached on sterile coverslips coated with 
0.2% gelatine (Sigma-Aldrich) by overnight incubation in complete endothelial cell basal medium 
under cell culture conditions. Erythrocytes prepared as indicated were perfused on a HUVEC 
monolayer in a flow chamber model (Oligene) at arterial shear rates (1,200−s). The interaction events 
were recorded with a charge-coupled device camera (Carl Zeiss) with ×20 magnification, followed 
by analysis of the number of adherent erythrocytes per high powerfield.  
6.1.8. Confocal microscopy and immunofluorescence 
For the visualisation of eryptotic erythrocytes, 4 µl of erythrocytes, incubated in respective 
experimental conditions, were stained with FITC-conjugated Annexin-V-Fluos (1:250 dilution; 
Roche, Mannheim, Germany) in 200 µl Ringer solution containing 5 mM CaCl2. Then the 
erythrocytes were washed twice and finally resuspended in 50 µl of Ringer solution containing 5 
mM CaCl2. 20 µl were smeared onto a glass slide, covered with a coverslip and images were 
subsequently taken on a Zeiss LSM 5 EXCITER confocal laser scanning microscope (Carl Zeiss 
MicroImaging, Oberkochen, Germany) with a water immersion Plan-Neofluar 63/1.3 NA DIC. 
6.1.9. Statistics 
Data are expressed as arithmetic means ± SEM. Statistical analysis was made using paired ANOVA 
with Tukey’s test as post-test, as appropriate. n denotes the number of different erythrocyte 
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specimens studied. The batches of erythrocytes differed moderately in their susceptibility to 
eryptosis. Thus, the control values were not identical in all series of experiments. To avoid any bias 
potentially introduced by the use of different erythrocyte batches, comparison was always made 
within a given erythrocyte batch. 
6.2 Stimulation of suicidal death of erythrocytes by phytochemicals 
6.2.1. Erythrocytes, solutions and chemicals 
Leukocyte-depleted erythrocytes were kindly provided by the blood bank of the University of 
Tübingen. The study is approved by the ethics committee of the University of Tübingen 
(184/2003V). Erythrocytes were incubated in vitro at a hematocrit of 0.4% in Ringer solution 
containing (in mM) 125 NaCl, 5 KCl, 1 MgSO4, 32 N-2-hydroxyethylpiperazine-N-2-ethanesulfonic 
acid (HEPES), 5 glucose, 1 CaCl2; pH 7.4 at 37°C for 48 h. Where indicated, erythrocytes were 
exposed to withaferin A (Enzo, Lörrach, Germany), oridonin (Enzo, Lörrach, Germany), dicoumarol 
(Sigma, Freiburg, Germany), amiloride and N-acetyl-L-cystein (both from Sigma, Freiburg, 
Germany) at the indicated concentrations. In Ca2+-free Ringer solution, 1 mM CaCl2 was substituted 
by 1 mM glycol-bis-(2-aminoethylether)-N,N,N',N'-tetraacetic acid (EGTA). Where indicated 
erythrocytes were incubated in the absence of MgSO4 and in presence of 1 mM CaCl2 and 1 mM 
EGTA.  
All incubations (48 hours) were carried out in Ringer solution containing 1 mM CaCl2 or where 
indicated in Ca2+-free Ringer solution. Following preteatment with the respective Ca2+ containing or 
Ca2+ free solutions for the indicated time periods the erythrocytes were washed with Ringer solution 
containing 5 mM CaCl2 and resuspended for 20 minutes with the same solution containing Annexin 
V-Fluos. The time period of 20 minutes is considered too short for the triggering of eryptosis.   
6.2.2. FACS analysis of annexin-V-binding and forward scatter  
After incubation under the respective experimental condition, 50 µl cell suspension was washed in 
Ringer solution containing 5 mM CaCl2 and then stained with Annexin-V-FITC (1:200 dilution; 
ImmunoTools, Friesoythe, Germany) in this solution at 37°C for 20 min under protection from light. 
In the following, the forward scatter (FSC) of the cells was determined, and annexin-V fluorescence 
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intensity was measured in FL-1 with an excitation wavelength of 488 nm and an emission 
wavelength of 530 nm on a FACS Calibur (BD, Heidelberg, Germany). 
6.2.3. Measurement of intracellular Ca2+ 
After incubation erythrocytes were washed in Ringer solution and then loaded with Fluo-3/AM 
(Biotium, Hayward, USA) in Ringer solution containing 5 mM CaCl2 and 2 µM Fluo-3/AM. The 
cells were incubated at 37°C for 30 min and washed twice in Ringer solution containing 5 mM 
CaCl2. The Fluo-3/AM-loaded erythrocytes were resuspended in 200 µl Ringer. Then, Ca2+-
dependent fluorescence intensity was measured in fluorescence channel FL-1 in FACS analysis. 
6.2.4. Determination of ceramide formation 
For the determination of ceramide, a monoclonal antibody-based assay was used. After incubation 
with and without withaferin A, cells were stained for 1 h at 37°C with 1 µg/ml anti-ceramide 
antibody (clone MID 15B4, Alexis, Grünberg, Germany) in PBS containing 0.1% bovine serum 
albumin (BSA) at a dilution of 1:5. The samples were washed twice with PBS-BSA. Subsequently, 
the cells were stained for 30 min with polyclonal fluorescein-isothiocyanate (FITC)-conjugated goat 
anti-mouse IgG and IgM specific antibody (Pharmingen, Hamburg, Germany) diluted 1:50 in PBS-
BSA. Unbound secondary antibody was removed by repeated washing with PBS-BSA. The samples 
were then analyzed by flow cytometric analysis in FL-1.  
6.2.5. Determination of intracellular ATP concentration 
For determination of intracellular erythrocyte ATP, 90 µl of erythrocyte pellets were incubated for 48 
h at 37°C in Ringer solution with or without oridonin (final hematocrit 5%). Additionally, 
erythrocytes were also incubated in glucose depleted Ringer solution as a positive control. All 
manipulations were then performed at 4°C to avoid ATP degradation. Cells were lysed in distilled 
water, and proteins were precipitated by addition of HClO4 (5%). After centrifugation, an aliquot of 
the supernatant (400 µl) was adjusted to pH 7.7 by addition of saturated KHCO3 solution. After 
dilution of the supernatant, the ATP concentrations of the aliquots were determined utilizing the 
luciferin–luciferase assay kit (Roche Diagnostics) on a luminometer (Berthold Biolumat LB9500, 
Bad Wildbad, Germany) according to the manufacturer's protocol. ATP concentrations are expressed 
in mmol/l cytosol of erythrocytes. 
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6.2.6. Measurement of hemolysis 
For the determination of hemolysis the samples were centrifuged (3 min at 400 g, room temperature) 
after incubation, and the supernatants were harvested. As a measure of hemolysis, the hemoglobin 
(Hb) concentration of the supernatant was determined photometrically at 405 nm. The absorption of 
the supernatant of erythrocytes lysed in distilled water was defined as 100% hemolysis. 
6.2.7. Estimation of ROS formation 
Oxidative stress was determined utilizing 2’,7’ dichlorodihydrofluorescein diacetate (DCFDA). 
After incubation, a 50 µl suspension of erythrocytes was washed in Ringer solution and then stained 
with DCFDA (Sigma, Schnelldorf, Germany) in Ringer solution containing DCFDA at a final 
concentration of 10 µM. Erythrocytes were incubated at 37°C for 30 min in the dark and then 
washed three times in Ringer solution. The DCFDA-loaded erythrocytes were resuspended in 200 µl 
Ringer solution, and ROS-dependent fluorescence intensity was measured in the fluorescence 
channel FL-1 of a FACS calibur (BD). 
6.2.8. Patch clamp recordings 
Patch clamp recordings were performed at room temperature. The patch electrodes were made of 
borosilicate glass capillaries (150 TF-10, Clark Medical Instruments) using a horizontal DMZ puller 
(Zeitz). Pipettes with high resistance from 17 to 20 MOhm were connected via an Ag-AgCl wire to 
the headstage of an EPC 9 patch-clamp amplifier (HEKA). Data acquisition and data analysis were 
controlled by a computer equipped with an ITC 16 interface (Instrutech) and by using Pulse software 
(HEKA). For current measurements, erythrocytes were held at a holding potential (Vh) of -10 mV, 
200 ms pulses from -100 to +100 mV were applied in increments of +20 mV. The original current 
traces are depicted without filtering (acquisition frequency of 3 kHz). The currents were analyzed by 
averaging the current values measured between 90 and 190 ms of each square pulse (current- voltage 
relationship). The applied voltages refer to the cytoplasmic face of the membrane with respect to the 
extracellular space. The offset potentials between both electrodes were zeroed before sealing. The 
liquid junction potentials between bath and pipette solutions, and between the bath solutions and the 
salt bridge (filled with NaCl bath solution) were calculated according to Barry and Lynch [40]. Data 
were corrected for liquid junction potentials. For whole cell recording, the pipette solutions consisted 
of (in mM): 125 Na-gluconate, 10 NaCl, 1 MgCl2, 1 MgATP, 1 EGTA, 10 HEPES/NaOH (pH 7.4). 
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The NaCl Ringer´s bath solution contained (in mM): 145 NaCl, 5 KCl, 2 MgCl2, 1 CaCl2, 5 glucose, 
10 HEPES/NaOH (pH 7.4). Cl- free bath solution contained (in mM): 150 Na-gluconate, 10 
HEPES/NaOH (pH 7.4). The NMDG-Cl and CaCl2 bath solutions contained (in mM): 180 NMDG 
or 100 CaCl2, 10 HEPES (titrated with NMDG or CaOH2 to pH 7.4). Chemicals were obtained from 
Sigma (Taufkirchen, Germany) and were of the highest grade available. Experiments were 
performed with or without a 3-6 hours exposure to dicoumarol. Sustained exposure resulted in 
eryptosis, which rendered the performance of patch clamp recordings difficult.   
6.2.9. Confocal microscopy and immunofluorescence 
For the visualisation of eryptotic erythrocytes, 4 µl of erythrocytes, incubated in the respective 
experimental conditions, were stained with FITC-conjugated Annexin-V-Fluos (1:250 dilution; 
Roche, Mannheim, Germany) in 200 µl Ringer solution containing 5 mM CaCl2. Then the 
erythrocytes were washed twice and finally re-suspended in 50 µl of Ringer solution containing 5 
mM CaCl2. 20 µl were smeared onto a glass slide, covered with a coverslip and images were 
subsequently taken on a Zeiss LSM 5 EXCITER confocal laser scanning microscope (Carl Zeiss 
MicroImaging, Oberkochen, Germany) with a water immersion Plan-Neofluar 63/1.3 NA DIC. 
6.2.10. Statistics 
Data are expressed as arithmetic means ± SEM. As indicated in the figure legends, statistical analysis 
was made using ANOVA with Tukey’s test as post-test and paired t test as appropriate. n denotes the 
number of different erythrocyte specimens studied. Since different erythrocyte specimens used in 
distinct experiments are differently susceptible to triggers of eryptosis, the same erythrocyte 
specimens have been used for control and experimental conditions. 
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7. RESULTS  
7.1. Stimulation of suicidal death of erythrocytes by mycotoxins 
7.1.1. Enniatin A 
In a first series of experiments, Fluo 3 fluorescence was employed to estimate cytosolic Ca2+ 
concentration. As illustrated in Fig. 13A and 13B, exposure of erythrocytes for 48 hours to Ringer 
solution containing enniatin A was followed by an increase of cytosolic Ca2+ concentration. When 
compared to erythrocytes exposed for 48 hours to Ringer solution without enniatin A, the 
cytosolic Ca2+ concentration was significantly higher at ≥ 2.5 µM enniatin A concentration. 
Additional experiments explored the effect of enniatin A during glucose depletion. As illustrated 
in Fig. 13C and 13D, glucose withdrawal similarly increased cytosolic Ca2+ activity, an effect 
augmented in the presence of enniatin A. The difference in cytosolic Ca2+ activity of glucose 
depleted erythrocytes between the presence and absence of enniatin A reached statistical 
significance at ≥ 2.5 µM enniatin A concentration.  
 
Fig. 13: Effect of enniatin A on erythrocyte cytosolic Ca2+ concentration  
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A. Original histogram of Fluo3 fluorescence in erythrocytes following exposure for 48 hours to Ringer solution 
without (-, black line) and with (+, red line) the presence of 5 µM enniatin A. B. Arithmetic means ± SEM (n = 12) of 
the geo means (geometric mean of the histogram in arbitrary units) of Fluo3 fluorescence in erythrocytes exposed for 
48 hours to Ringer solution without (white bar) or with (black bars) enniatin A. *** indicates significant difference 
(p<0.001) from the respective value in the absence of enniatin A (ANOVA). C. Original histogram of Fluo3 
fluorescence in erythrocytes following exposure for 48 hours to Ringer solution without glucose, without (-, black 
line) and with the (+, red line) presence of 5 µM enniatin A. D. Arithmetic means ± SEM (n = 12) of the geo means 
(geometric mean of the histogram in arbitrary units) of Fluo3 fluorescence in erythrocytes exposed for 48 hours to 
Ringer solution without glucose in absence (white bar) or in presence (black bars) of enniatin A. The broken line 
indicates control Fluo3 fluorescence in the presence of glucose and absence of enniatin A. *** indicates significant 
difference (p<0.001) from the respective value in the absence of enniatin A (ANOVA). 
As Ca2+ activates K+ channels with subsequent exit of KCl and cell shrinkage, forward scatter 
was determined to reveal a possible effect of enniatin A on cell volume. As shown in Fig. 14A 
and 14B, exposure of erythrocytes for 48 hours to Ringer solution containing enniatin A was 
indeed followed by a decrease of forward scatter, an effect reaching statistical significance at 1 
µM enniatin A.  As shown in Fig. 14C and 14D, glucose withdrawal was again followed by a 
decrease of forward scatter, reflecting cell shrinkage. The administrartion of 1 µM enniatin A was 
followed by a further significant decrease of forward scatter. However, at a concentration of 5 µM 
enniatin A, the forward scatter of the glucose depleted erythrocytes was significantly higher than 
the forward scatter of glucose depleted erythrocytes in the absence of enniatin A.  
 
Fig. 14: Effect of enniatin A on erythrocyte forward scatter  
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A. Original histogram of forward scatter of erythrocytes following exposure for 48 hours to Ringer solution without 
(-, black line) and with (+, red line) the presence of 5 µM enniatin A. B. Arithmetic means ± SEM (n = 12) of the 
erythrocyte forward scatter following incubation for 48 hours in Ringer solution without (white bar) or with (black 
bars) 1-5 µM enniatin A. *** (p<0.001) indicate significant difference from the absence of enniatin A (ANOVA). C. 
Original histogram of forward scatter of erythrocytes following exposure for 48 hours to Ringer solution without 
glucose, without (-, black line) and with (+, red line) presence of 5 µM enniatin A. D. Arithmetic means ± SEM (n = 
12) of the erythrocyte forward scatter following incubation for 48 hours in Ringer solution without glucose, in the 
absence (white bar) or presence (black bars) of 1-5 µM enniatin A. The broken line indicates control forward scatter 
in the presence of glucose and absence of enniatin A. **, *** (p<0.01, p<0.001) indicate significant difference from 
the absence of enniatin A (ANOVA).  
Ca2+ further stimulates cell membrane scrambling with phosphatidylserine exposure at the cell 
surface. To estimate an effect of enniatin A on cell membrane scrambling, phosphatidylserine 
exposing erythrocytes were identified utilizing annexin V-binding. In a first approach, annexin V 
binding cells were visualized utilizing confocal microscopy (Fig. 15). The number of annexin V 
positive erythrocytes was higher following treatment (for 48 hours) with enniatin A than 
following incubation (for 48 hours) in Ringer solution without enniatin A. 
                        
Fig. 15: Confocal images of PS-exposing erythrocytes exposed to enniatin A 
Confocal microscopy of FITC-dependent fluorescence (lower panels) and light microscopy (upper panels) of human 
erythrocytes stained with FITC-conjugated Annexin-V-Fluos following 48 hours incubation in Ringer solution 
without (left panels) and with (right panels) 5 µM enniatin A.  
To quantify the effect of enniatin A on cell membrane scrambling, annexin V-binding 
erythrocytes were counted in FACS analysis. As displayed in Fig. 16A and 16B, the percentage of 
annexin V binding erythrocytes was significantly higher following exposure of erythrocytes for 
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48 hours to Ringer solution containing ≥2.5 µM enniatin A than following exposure of 
erythrocytes for 48 hours to Ringer solution without enniatin A. Glucose withdrawal further 
enhanced the percentage of annexin V binding erythrocytes. As shown in Fig. 16C and 16D, the 
percentage of annexin V binding erythrocytes was higher in glucose depleted cells exposed to 
enniatin A than in glucose depleted cells without enniatin A exposure. The difference of the 
percentage annexin V binding erythrocytes between the presence and absence of enniatin A was 
statistically significant at ≥ 1 µM enniatin A.  
Further experiments were performed to reveal a possible hemolytic action of enniatin A. To this 
end, hemoglobin release was determined following exposure of the erythrocytes to Ringer 
solution for 48 hours without or with 1-5 µM enniatin A. As indicated in Fig. 4B, the exposure to 
enniatin was followed by hemolysis, an effect reaching statistical significance at 2.5 µM enniatin 
A. Following enniatin A exposure, the percentage of hemolysed erythrocytes was, however, one 
magnitude smaller than the percentage of phosphatidylserine exposing erythrocytes. Collectively, 
the above results reveal that enniatin A triggers phospholipid scrambling and to a clearly lesser 
extent hemolysis. 
 
Fig. 16: Effect of enniatin A on phosphatidylserine exposure and erythrocyte membrane integrity 
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A. Original histogram of annexin V binding of erythrocytes following exposure for 48 hours to Ringer solution 
without (-, black line) and with (+, red line) presence of 5 µM enniatin. B. Arithmetic means ± SEM (n = 12) of 
erythrocyte annexin V binding following incubation for 48 hours in Ringer solution without (white bar) or with 
(black bars) the presence of 1-5 µM enniatin A. For comparison, arithmetic means ± SEM (n = 4) of the percentage 
of hemolysis is shown as grey bars. *, *** (p<0.05, p<0.001) indicate significant difference from the absence of 
enniatin A (ANOVA). C. Original histogram of annexin V binding of erythrocytes following exposure for 48 hours 
to Ringer solution without glucose in the absence (-, black line) and presence (+, red line) of 5 µM enniatin A. D. 
Arithmetic means ± SEM (n = 12) of erythrocyte annexin V binding following incubation for 48 hours in the absence 
of glucose in the absence (white bar) or presence (black bars) of 1-5 µM enniatin A. The broken line indicates control 
annexin V binding in the presence of glucose and absence of enniatin A. **, *** (p<0.01, p<0.001) indicate 
significant difference from the absence of enniatin A (ANOVA).  
The parallel alteration of cytosolic Ca2+ activity and cell membrane srambling was suggestive for 
a causal role of Ca2+ in the triggering of cell membrane scrambling following enniatin A 
exposure. To test, whether enniatin A-induced cell membrane scrambling was indeed dependent 
on Ca2+, erythrocytes were treated with enniatin A in the presence and nominal absence of 
extracellular Ca2+. As shown in Fig. 17A, the effect of enniatin A on annexin V-binding was 
significantly blunted but not fully abolished in the nominal absence of Ca2+. Furthermore, the 
cation channel inhibitor amiloride (1 mM) blunted but not abolished the effect of enniatin A on 
annexin V-binding (Fig. 17B). Further experiments were performed to test, whether enniatin A-
induced cell membrane scrambling required the activation of caspases. To this end, erythrocytes 
were treated with enniatin A in the absence and presence of the pancaspase inhibitor zVAD. As 
shown in Fig. 17D, the effect of enniatin A on annexin V-binding was not significantly modified 
by zVAD (10 µM). As a positive control, erythrocytes were treated with zVAD (10 µM) for 48 
hours and then exposed to oxidative stress using t-BOOH (0.3 mM) for 30 minutes. zVAD 
treatment significantly attenuated the enhanced annexin V-binding induced by oxidative stress 
(Fig. 17E).  Further experiments explored the impact of kinases on enniatin A induced cell 
membrane scrambling. The kinase inhibitor staurosporine (500 nM) blunted the effect of enniatin 
A on annexin V-binding (Fig. 17C).    
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Fig. 17: Effect of Ca2+ withdrawal, cation channel, caspase and protein kinase C inhibition on enniatin 
A induced phosphatidylserine exposure 
A. Arithmetic means ± SEM (n = 4) of the percentage of annexin V-binding erythrocytes after a 48 hours treatment 
with Ringer solution without (white bar) or with (black bars) 5 µM enniatin A in the presence (left bars, +Ca2+) and 
absence (right bars, -Ca2+) of calcium. *** (p<0.001) indicate significant difference from the absence of enniatin A 
(ANOVA), # indicates significant difference (p<0.05) from the respective values in the presence of Ca2+. B. 
Arithmetic means ± SEM (n = 5) of the percentage of annexin V-binding erythrocytes after a 48 hours treatment with 
Ringer solution without (white bar) or with (black bars) 5 µM enniatin A in the absence of amiloride (1 mM) (left 
bars) and presence of amiloride (1 mM) (right bars). *** (p<0.001) indicate significant difference from the absence 
of enniatin A (ANOVA), ### indicates significant difference (p<0.001) from the respective values in the absence of 
amiloride. C. Arithmetic means ± SEM (n = 4) of the percentage of annexin V-binding erythrocytes after a 48 hours 
treatment with Ringer solution without (white bar) or with (black bars) 5 µM enniatin A in the absence (left bars, - 
staurosporine) and presence (right bars, + staurosporine) of staurosporine (500 nM). *** (p<0.001) indicate 
significant difference from the absence of enniatin A (ANOVA). # indicates significant difference (p<0.05) from the 
respective value in the absence of staurosporine. D. Arithmetic means ± SEM (n = 4) of the percentage of annexin V-
binding erythrocytes after a 48 hours treatment with Ringer solution without (white bar) or with (black bars) 2.5 µM 
and 5 µM enniatin A in the absence (left bars, - zVAD) and presence (right bars, +zVAD) of zVAD (10 µM). *, *** 
(p<0.05, p<0.001) indicate significant difference from the absence of enniatin A (ANOVA). E. Arithmetic means ± 
SEM (n = 9) of the percentage of annexin V-binding erythrocytes after a 48 hours treatment with Ringer solution 
without (white bar) or with (black bars) 10 µM zVAD in the absence (left bars, - Oxidation) and presence (right bars, 
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+ Oxidation) of t-BOOH (0.3 mM). *, *** (p<0.05, p<0.001) indicate significant difference from the absence of t-
BOOH (ANOVA). # indicates significant difference (p<0.05) from the absence of zVAD. 
Phospholipid scrambling could be triggered by energy depletion. Accordingly, additional 
experiments were performed to determine, whether enniatin A exposure influences intracellular 
ATP concentrations in erythrocytes. As shown in Fig. 18, a 48 hours exposure of human 
erythrocytes to enniatin A (≥ 2.5 µM) significantly reduced the cellular ATP concentration. 
Intracellular ATP concentration in erythrocytes incubated in glucose-depleted Ringer solution 
was similarly decreased significantly.  
 
Fig. 18: Effect of enniatin A on erythrocyte cytosolic ATP content 
Arithmetic means ± SEM (n = 4) of the ATP concentration after a 48 hours incubation in Ringer solution without 
(white bar) or with (black bars) enniatin A at the indicated concentrations, or in glucose-depleted Ringer solution 
(grey bar, minus glucose) **, *** (p<0.01, p<0.001) indicates significant difference from control (absence of enniatin 
A and presence of glucose) (ANOVA). 
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7.1.2. Ochratoxin A 
In order to determine, whether ochratoxin A stimulates Ca2+-entry into erythrocytes, cytosolic 
Ca2+-activity was estimated from Fluo3-fluorescence. Erythrocytes were loaded with Fluo3-AM 
and the Fluo3-fluorescence determined in FACS analysis. As illustrated in Fig. 19, a 48 hours 
exposure of human erythrocytes to ochratoxin A was followed by an increase of Fluo3-
fluorescence, an effect reaching statistical significance at 2.5 µM ochratoxin A concentration.  
 
Fig. 19. Effect of ochratoxin A on erythrocyte cytosolic Ca2+ concentration.  
A. Original histogram of Fluo3-fluorescence in erythrocytes following exposure for 48 hours to Ringer solution 
without (-, black line) and with (+, red line) presence of ochratoxin A (10 µM). B. Arithmetic means ± SEM (n = 12) 
of the normalized geo means (geometric mean of the histogram in arbitrary units) of Fluo3-fluorescence in 
erythrocytes exposed for 48 hours to Ringer solution without (white bar) or with (black bars) ochratoxin A (1-10 
µM). * (p<0.05), *** (p<0.001) indicates significant difference from the absence of ochratoxin A (ANOVA). 
An increased cytosolic Ca2+-concentration is expected to stimulate Ca2+-sensitive K+-channels 
with subsequent K+-exit, hyperpolarisation, Cl--exit and loss of cell water due to cellular loss of 
KCl. To explore, whether ochratoxin A influences cell volume, forward scatter was determined in 
FACS analysis. As shown in Fig. 20, a 48 h treatment with ochratoxin A was followed by a 
decrease of forward scatter, an effect reaching statistical significance at 5 µM ochratoxin A 
concentration. 
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Fig. 20. Effect of ochratoxin A on erythrocyte forward scatter.  
A. Original histogram of forward scatter of erythrocytes following exposure for 48 hours to Ringer solution without 
(-, black line) and with (+, red line) presence of ochratoxin A (10 µM). B. Arithmetic means ± SEM (n = 12) of the 
normalized erythrocyte forward scatter (FSC) following incubation for 48 hours to Ringer solution without (white 
bar) or with (black bars) ochratoxin A (1-10 µM). * (p<0.05), *** (p<0.001) indicates significant difference from the 
absence of ochratoxin A (ANOVA). 
Increased cytosolic Ca2+ is further expected to stimulate erythrocyte membrane scrambling with 
phosphatidylserine exposure at the erythrocyte surface. Accordingly, a further series of 
experiments explored whether ochratoxin A triggers cell membrane scrambling. 
Phosphatidylserine exposing erythrocytes were identified with binding of fluorescent annexin-V 
to the erythrocyte surface. As illustrated in Fig. 21, a 48 hours exposure to ochratoxin A resulted 
in an increase of annexin-V-binding, an effect reaching statistical significance at 2.5 µM 
ochratoxin A.  
Further experiments addressed, whether ochratoxin A treatment triggers hemolysis, which was 
estimated from hemoglobin release into the supernatant. As shown in Fig. 21, exposure of 
erythrocytes to ochratoxin A for 48 hours led to a slight increase of hemoglobin concentration in 
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the supernatant, an effect reaching statistical significance at 10 µM. 
 
Fig. 21. Effect of ochratoxin A on phosphatidylserine exposure and hemolysis.  
A. Original histogram of annexin V binding of erythrocytes following exposure for 48 hours to Ringer solution 
without (-, black line) and with (+, red line) presence of ochratoxin A (10 µM). B. Arithmetic means ± SEM of 
erythrocyte annexin-V-binding (n = 12) following incubation for 48 hours to Ringer solution without (white bar) or 
with (black bars) presence of ochratoxin A (1-10 µM). For comparison, arithmetic means ± SEM (n = 4) of the 
percentage of hemolysis is shown as grey bars. * (p<0.05), ** (p<0.01),*** (p<0.001) indicates significant difference 
from the absence of ochratoxin A (ANOVA). 
An additional series of experiments explored, whether the ochratoxin A induced cell membrane 
scrambling resulted from Ca2+ entry. To this end, erythrocytes were treated with 10 µM 
ochratoxin A in the presence or in the nominal absence of extracellular Ca2+. As shown in Fig. 22, 
Ca2+-removal indeed blunted significantly the increase of annexin-V-binding following 
ochratoxin A treatment. However, the percentage of phosphatidylserine exposing erythrocytes 
still increased significantly following ochratoxin A treatment in the nominal absence of Ca2+. 
Thus, Ca2+-removal significantly blunted, but did not fully abrogate the ochratoxin A induced 
erythrocyte membrane scrambling. 
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Fig. 22. Effect of Ca2+ withdrawal on ochratoxin A- induced annexin-V-binding.  
Arithmetic means ± SEM (n = 4) of the percentage of annexin V-binding erythrocytes after a 48 hours 
treatment with Ringer solution without (white bar) or with (black bars) ochratoxin A (10 µM) in the 
presence (left bars, +Calcium) and absence (right bars, -Calcium) of Ca2+. * (p<0.05), *** (p<0.001) 
indicates significant difference from the absence of ochratoxin A (ANOVA) # (p<0.05) indicates 
significant difference from the respective value in the presence of Ca2+. 
Additional experiments were performed to explore, whether ochratoxin A stimulates the 
formation of ceramide, which is known to enhance the Ca2+-sensitivity of cell membrane 
scrambling and thus to trigger eryptosis. Ceramide abundance at the erythrocyte surface was 
quantified utilizing FITC-labeled anti-ceramide antibodies. As shown in Fig. 23, ochratoxin A (10 
µM) significantly increased ceramide formation. Additional experiments explored the effect of 
the sphingomyelinase inhibitor amitriptyline. Treatment with ochratoxin A significantly enhanced 
annexin V binding from 2.9 ± 0.1% (n = 4) to 26.4 ± 1.5% (n = 4) in the absence and to 31.8 ± 
0.2% (n = 4) in the presence of amitriptyline (10 µM). Thus, amitriptyline did not significantly 
modify annexin binding following ochratoxin A treatment.  
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Fig. 23. Effect of ochratoxin A on ceramide formation.  
A. Original histogram of anti-ceramide FITC-fluorescence in erythrocytes following exposure for 48 hours 
to Ringer solution without (-, black line) and with (+, red line) presence of ochratoxin A (10 µM). B. 
Arithmetic means ± SEM (n = 4) of ceramide abundance after a 48 h incubation in Ringer solution without 
(white bar) or with (black bars) ochratoxin A (10 µM). *** (p<0.001) indicates significant difference from 
control (absence of ochratoxin A) (t test). 
Further experiments explored whether or not ochratoxin A influences the energy status of 
erythrocytes. To this end, cytosolic ATP concentrations were determined. As a result, the ATP 
concentrations were virtually identical in the presence (2.7 ± 0.1 mM; n = 4) and absence (2.7 ± 
0.1 mM; n = 4) of ochratoxin A. Thus, ochratoxin induced suicidal death of erythrocytes did not 
result from ATP depletion of erythrocytes.  
Phosphatidylserine exposing erythrocytes are expected to adhere to the vascular wall. Thus, 
additional experiments were performed to test for an effect of  ochratoxin A on adherence of 
erythrocytes to human umbilical vein endothelial cells (HUVEC) under in vitro flow conditions at 
arterial shear rates of 1200-s. As illustrated in Fig. 24, treatment of erythrocytes with ochratoxin A 
(10 µM) was followed by a marked increase of the number of erythrocytes adhering to HUVEC. 
 63 
                                      
Fig. 24. Effect of ochratoxin A on adhesion of erythrocytes under flow conditions.  
Arithmetic means ± SEM (n = 4) of erythrocytes binding to human umbilical vein endothelial cells 
(HUVEC) under flow conditions following exposure for 48 hours to Ringer solution without (white bar), 
or with ochratoxin A (10 µM) (black bar). *** (p<0.001) indicates statistically significant difference from 
the absence of ochratoxin A (10 µM). 
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7.1.3. Zearalenone 
The present study addressed the effect of zearalenone on suicidal erythrocyte death or eryptosis. 
The most important stimulator of eryptosis is increase of cytosolic Ca2+ activity. Thus, Fluo3 
fluoresence was employed to estimate [Ca2+]i in erythrocytes without or with prior exposure to 
zearalenone (1 – 50 µM) in Ringer solution. Following incubation the erythrocytes were loaded 
with Fluo3-AM and Fluo3 fluorescence determined in FACS analysis. As illustrated in Fig. 25, a 
48 hours exposure of human erythrocytes to zearalenone (≥ 25 µM) was followed by a significant 
increase of Fluo3 fluorescence. 
 
Fig. 25: Effect of zearalenone on erythrocyte cytosolic Ca2+ concentration  
A. Original histogram of Fluo3 fluorescence in erythrocytes following exposure for 48 h to Ringer solution without (-
) and with (+) presence of 50 µM zearalenone.B. Arithmetic means ± SEM (n = 12) of the Fluo3 fluorescence 
(arbitrary units) in erythrocytes exposed for 48 h to Ringer solution without (white bar) or with (black bars) 
zearalenone (1 – 50 µM). * (p<0.05), ***(P<0.001) indicate significant difference from the absence of zearalenone 
(ANOVA). 
An increase of [Ca2+]i is expected to activate Ca2+ sensitive K+ channels with subsequent KCl exit 
and thus cell shrinkage. In a next series of experiments erythrocyte volume was estimated from 
forward scatter in FACS analysis. As illustrated in Fig. 26, a 48 hours exposure to zearalenone 
was followed by a decrease of forward scatter, an effect reaching statistical significance at 10 µM 
zearalenone concentration.  
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Fig. 26: Effect of zearalenone on erythrocyte forward scatter  
A. Original histogram of forward scatter of erythrocytes following exposure for 48 h to Ringer solution without (-) 
and with (+) presence of 50 µM zearalenone. B. Arithmetic means ± SEM (n = 12) of the normalized erythrocyte 
forward scatter (FSC) following incubation for 48 h to Ringer solution without (white bar) or with (black bars) 
zearalenone (1 – 50 µM).) **(p<0.01), ***(p<0.001) indicates significant difference from the absence of zearalenone 
(ANOVA). 
An increase of [Ca2+]i is further expected to trigger cell membrane scrambling with 
phosphatidylserine exposure at the cell surface. Phosphatidylserine exposing erythrocytes were 
identified by determination of annexin-V-binding in FACS analysis. As shown in Fig. 27, a 48 h 
exposure to zearalenone increased the percentage of annexin-V-binding erythrocytes, an effect 
reaching statistical significance at ≥ 25 µM zearalenone concentration.  
Additional experiments were performed to expore whether zearalenone induces hemolysis, which 
was estimated by determination of hemoglobin in the supernatant. As illustrated in Fig, 28, the 
percentage of hemolysed erythrocytes increased slightly but significantly following exposure of 
erythrocytes for 48 h to zearalenone.  
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Fig. 28: Effect of zearalenone on phosphatidylserine exposure and hemolysis   
A. Original histogram of annexin-V-binding of erythrocytes following exposure for 48 h to Ringer solution without (-
) and with (+) presence of 50 µM zearalenone. B. Arithmetic means ± SEM (n = 12) of erythrocyte annexin-V-
binding following incubation for 48 h to Ringer solution without (white bar) or with (black bars) presence of 
zearalenone (1 – 50 µM). For comparison, arithmetic means ± SEM (n = 4) of the percentage of hemolysis is shown 
as grey bars. * (p<0.05), ***(P<0.001) indicate significant difference from the absence of zearalenone (ANOVA). 
In order to quantify the contribution of Ca2+ entry from the extracellular space for the triggerung 
of eryptosis, erythrocytes were exposed to 25 µM zearalenone for 48 hours in either the presence 
of 1 mM extracellular Ca2+ or in the absence of extracellular Ca2+ and presence of the Ca2+ 
chelator EGTA (1 mM). As shown in Fig. 29, the effect of zearalenone on annexin-V-binding was 
significantly decreased in the nominal absence of Ca2+. In the absence of extracellular Ca2+ the 
percentage annexin V binding erythrocytes still tended to be higher following zearalenone 
treatment than without zearalenone treatment, a difference, however, not reaching statistical 
significance.  
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Fig. 29: Effect of Ca2+ withdrawal on zearalenone- induced annexin-V-binding 
Arithmetic means ± SEM (n = 4 of the percentage of annexin-V-binding erythrocytes after a 48 h treatment with 
Ringer solution without (white bar) or with (black bars) 25 µM zearalenone in the presence (left bars, + Calcium) and 
absence (right bars, - Calcium) of calcium. *** (p<0.01) indicates significant difference from the absence of 
zearalenone (ANOVA) ###(p<0.001) indicates significant difference from the respective values in the presence of 
Ca2+. 
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7.2. Stimulation of suicidal death of erythrocytes by phytochemicals 
7.2.1. Withaferin A 
A hallmark of eryptosis is cell shrinkage which is apparent from a decrease of forward scatter. In 
order to test, whether withaferin A exposure leads to cell shrinkage, forward scatter was 
determined in FACS analysis. As shown in Fig.30, treatment of human erythrocytes for 48 hours 
with withaferin A was followed by a decrease of forward scatter, an effect reaching statistical 
significance at 5 µM concentration. 
 
Fig. 30: Effect of withaferin A on erythrocyte forward scatter  
A. Original histogram of forward scatter of erythrocytes following exposure for 48 h to Ringer solution without (-) 
and with (+) presence of 10 µM withaferin A. B. Arithmetic means ± SEM (n = 12) of the normalized erythrocyte 
forward scatter (FSC) following incubation for 48 h to Ringer solution without (white bar) or with (black bars) 
withaferin A (1 – 10 µM). **(p<0.01), *** (p<0.001) indicates significant difference from the absence of withaferin 
A (ANOVA). 
The second hallmark of eryptosis is cell membrane scrambling with phosphatidylserine exposure 
at the cell surface. In order to test whether withaferin A treatment triggers cell membrane 
scrambling, phosphatidylserine exposing erythrocytes were identified by measurement of 
annexin-V-binding in FACS analysis. As illustrated in Fig. 31, a 48 h exposure to withaferin A 
increased the percentage of annexin-V-binding erythrocytes, an effect reaching statistical 
significance at 5 µM concentrations. To rule out an effect of solvent, annexin-V-binding was 
estimated in erythrocytes exposed to DMSO (0.2%). As a result, annexin-V-binding was not 
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significantly different following incubation in the absence (2.3 ± 0.0%, n = 4). and presence (2.4 
± 0.1%, n = 4) of DMSO (0.2%).  
Further experiments explored whether treatment with withaferin A is followed by hemolysis, 
which was calculated from hemoglobin release into the supernatant. As shown in Fig. 32, 
exposure of erythrocytes for 48 h to withaferin A increased the hemoglobin concentration in the 
supernatant, an effect reaching statistical significance at 5 µM (Fig. 32B). The percentage of 
hemolysed erythrocytes was, however, ~5-fold smaller than the percentage of phosphatidylserine 
exposing cells.  
In order to correlate cell shrinkage with phosphatidylserine exposure, a dot plot analysis of the 
histograms was performed. As shown in Fig. 32C and 32D, the percentage of annexin-V positive 
erythrocytes is significantly enhanced upon treatment with withaferin A in both sub-populations 
of cells with lower (<400, arb. units) and higher cell volumes (>400, arb. units).  
 
Fig. 32: Effect of withaferin A on phosphatidylserine exposure and hemolysis   
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A. Original histogram of annexin-V-binding of erythrocytes following exposure for 48 h to Ringer solution without (-
) and with (+) presence of 10 µM withaferin A. B. Arithmetic means ± SEM of erythrocyte annexin-V-binding (n = 
12) following incubation for 48 h to Ringer solution without (white bar) or with (black bars) presence of withaferin A 
(1 – 10 µM). For comparison, arithmetic means ± SEM (n = 4) of the percentage of hemolysis is shown as grey bars. 
* (p<0.05), ** (p<0.01), *** (p<0.001) indicates significant difference from the absence of withaferin A (ANOVA). 
C. Original dot plots of FSC versus Annexin-V fluorescence of erythrocytes following exposure for 48 h  to Ringer 
solution without (left panel) and with (right panel) the presence of 10 µM withaferin A. D. Arithmetic means ± SEM 
of annexin-V positive erythrocytes (n = 4) with decreased cell volume (<400, arb. units) and increased cell volume 
(>400, arb. units) following incubation for 48 h in Ringer solution without (white bars) or with (black bars) presence 
of withaferin A (10 µM). ** (p<0.01) indicates significant difference from the absence of withaferin A (t test). 
Both, cell shrinkage and cell membrane scrambling could result from increase of cytosolic Ca2+ 
activity. In order to determine cytosolic Ca2+ activity, erythrocytes were loaded with Fluo 3 and 
the Fluo3 fluorescence was determined by FACS analysis. As illustrated in Fig. 33, treatment of 
human erythrocytes with withaferin A increased Fluo3 fluorescence, an effect reaching statistical 
significance at 5 µM withaferin A concentration. Thus, withaferin A treatment increases cytosolic 
Ca2+ concentration in a subpopulation of human erythrocytes. A dot plot analysis of the 
histograms was performed to correlate cell shrinkage with cytosolic Ca2+ activity. As shown in 
Fig. 33C and 33D, the percentage of Fluo3 positive erythrocytes is significantly enhanced upon 
treatment with withaferin A in both sub-populations of cells with lower (<400, arb. units) and 
higher cell volumes (>400, arb. units).  
 
Fig. 33: Effect of withaferin A on erythrocyte cytosolic Ca2+ concentration  
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A. Original histogram of Fluo3 fluorescence in erythrocytes following exposure for 48 h to Ringer solution without (-
) and with (+) presence of 10 µM withaferin A. B. Arithmetic means ± SEM (n = 12) of the normalized geo means of 
Fluo3 fluorescence in erythrocytes exposed for 48 h to Ringer solution without (white bar) or with (black bars) 
withaferin A (1 – 10 µM). *** (p<0.001) indicates significant difference from the absence of withaferin A 
(ANOVA). C. Original dot plots of FSC versus Fluo3 fluorescence of erythrocytes following exposure for 48 h to 
Ringer solution without (left panel) and with (right panel) the presence of 10 µM withaferin A. D. Arithmetic means 
± SEM of Fluo3 positive erythrocytes (n = 4) with decreased cell volume (<400, arb. units) and increased cell volume 
(>400, arb. units) following incubation for 48 h in Ringer solution without (white bars) or with (black bars) presence 
of withaferin A (10 µM). *** (p<0.001) indicates significant difference from the absence of withaferin A (t test). 
In order to test, whether the increase of cytosolic Ca2+ activity was required for the stimulation of 
cell membrane scrambling by withaferin A, erythrocytes were exposed to 10 µM withaferin A in 
the presence or in the nominal absence of extracellular Ca2+. As shown in Fig. 34A, the effect of 
withaferin A on annexin-V-binding was significantly blunted in the nominal absence of Ca2+. 
However, even in the nominal absence of Ca2+, withaferin A significantly stimulated annexin-V-
binding. Accordingly, Ca2+ entry and subsequent increase of cytosolic Ca2+ activity contributed to 
but did not fully account for the stimulation of erythrocyte membrane scrambling following 
treatment with withaferin A. To test, whether eryptosis was influenced by Mg2+, further 
experiments were performed in the presence and absence of Mg2+ and in the presence of EGTA 
and absence of Ca2+. As a result,  in this series the treatment with withaferin A (10 µM) increased 
the percentage of annexin-V-binding cells from 3.4 ± 0.2 % to 12.0  ±  0.7%  (n = 4) in the 
presence of Mg2+ and from 3.5 ± 0.2 to 12.2  ± 0.9%  (n = 4) in the absence of Mg2+, values not 
significantly different. Similar to extracellular Ca2+ removal, the non selective cation channel 
blocker amiloride (1 mM) significantly blunted withaferin-triggered phosphatidylserine exposure 
(Fig. 34B). 
 
Fig. 34: Role of Ca2+ in withaferin A- induced annexin-V-binding 
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A. Arithmetic means ± SEM (n = 4) of the percentage of annexin-V-binding erythrocytes after a 48 h treatment with 
Ringer solution without (white bars) or with (black bars) 10 µM withaferin A in the presence (left bars, +Ca2+) and 
absence (right bars, -Ca2+) of calcium. * (p<0.05), *** (p<0.001) indicates significant difference from the absence of 
withaferin A (ANOVA), # (p<0.05) indicates significant difference from the respective values in the presence of 
Ca2+. B. Arithmetic means ± SEM (n = 4) of the percentage of annexin-V-binding erythrocytes after a 48 h treatment 
with Ringer solution without (white bars) or with (black bars) 10 µM withaferin A in the presence (left bars, -
amiloride) and absence (right bars, +amiloride) of amiloride (1 mM). *** (p<0.001) indicates significant difference 
from the absence of withaferin A (ANOVA), ### (p<0.001) indicates significant difference from the respective 
values in the absence of amiloride. 
As a next step, the effect of withaferin A on oxidative stress was tested by measuring 2’,7’ 
dichlorodihydrofluorescein diacetate (DCFDA) fluorescence. Exposure of erythrocytes to 
withaferin A (10 µM) was followed by a significant increase in DCFDA-dependent fluorescence 
pointing to oxidative stress (Fig. 35A and 35B). To examine the role of oxidative stress in 
withaferin A-induced eryptosis, the effect of the antioxidant scavenger N-acetyl-L-cysteine 
(NAC) was tested. As shown in Fig. 35C, 1mM NAC significantly blunted the increase in 
phosphatidylserine-exposing erythrocytes induced by withaferin A. These observations point to 
oxidative stress in withaferin A-induced suicidal erythrocyte death. 
 
Fig. 35: Effect of withaferin A on generation of reactive oxygen species 
A. Original histogram of DCFDA-positive erythrocytes following exposure for 48 h to Ringer solution without (-, 
black line) and with (+, red line) 10 µM withaferin A. B. Arithmetic means ± SEM (n = 4) of the percentage of 
DCFDA-positive erythrocytes following incubation for 48 h to Ringer solution without (white bar) or with (black 
bar) 10 µM withaferin A. *** (p<0.001) indicates significant difference from the absence of withaferin A (ANOVA). 
C. Arithmetic means ± SEM (n = 4) of the percentage of annexin-V-binding erythrocytes after a 48 h treatment with 
Ringer solution without (white bars) or with (black bars) 10 µM withaferin A in the absence (left bars, -NAC) and 
presence (right bars, +NAC) of 1 mM N-acetyl-cysteine (NAC). *** (p<0.001) indicates significant difference from 
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the absence of withaferin A (ANOVA), # (p<0.05) indicates significant difference from the respective values in the 
absence of NAC (ANOVA). 
The sensitivity of eryptosis to cytosolic Ca2+ activity could be enhanced by ceramide. An 
additional series of experiments thus explored the effect of withaferin A treatment on the 
formation of ceramide. Ceramide abundance was determined utilizing FITC-labeled anti-
ceramide antibodies. As illustrated in Fig. 36A and 36B, withaferin A significantly increased 
ceramide-dependent fluorescence.   
 
Fig. 36. Effect of withaferin A on ceramide formation.  
A. Original histogram of ceramide-dependent fluorescence in erythrocytes following exposure for 48 h to Ringer 
solution without (-) and with (+) presence of 10 µM withaferin. B. Arithmetic means ± SEM (n = 8) of ceramide 
abundance after a 48 h incubation in Ringer solution without (white bar) or with (black bar) withaferin A (10 µM). 
*** (p<0.001) indicates significant difference from control (absence of withaferin A) (ANOVA). 
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7.2.2. Oridonin 
Cytosolic Ca2+ concentration was estimated utilizing Fluo 3 fluorescence. As illustrated in Fig. 
37, exposure of human erythrocytes to Ringer solution containing oridonin was followed by an 
increase of cytosolic Ca2+ concentration, an effect reaching statistical significance at an oridonin 
concentration of 10 µM.   
 
Fig. 37: Effect of oridonin on erythrocyte cytosolic Ca2+ concentration  
A. Original histogram of Fluo3 fluorescence in erythrocytes following exposure for 48 hours to Ringer solution 
without (-, black line) and with (+, red line) presence of 50 µM oridonin. B. Arithmetic means ± SEM (n = 8) of the 
geo means (geometric mean of the histogram in arbitrary units) of Fluo3 fluorescence in erythrocytes exposed for 48 
hours to Ringer solution without (white bar) or with (black bars) 1-50 µM oridonin. * (p<0.05), *** (p<0.001) 
indicate significant difference from the absence of oridonin (ANOVA). 
As Ca2+ activates the  Ca2+ sensitive K+ channels, an increase of  cytosolic Ca2+ concentration is 
expected to result in exit of KCl with osmotically obliged water thus leading to cell shrinkage. 
Accordingly, forward scatter was determined to analyze the effect of oridonin on cell volume. As 
demonstrated in Fig. 38, exposure of erythrocytes for 48 hours to Ringer solution containing 
oridonin was indeed followed by a decrease of forward scatter, an effect reaching statistical 
significance at an oridonin concentration of 25 µM.   
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Fig. 39: Effect of oridonin on erythrocyte forward scatter  
A. Original histogram of forward scatter of erythrocytes following exposure for 48 hours to Ringer solution without 
(-, black line) and with (+, red line) presence of 50 µM oridonin. B. Arithmetic means ± SEM (n = 8) of the 
erythrocyte forward scatter following incubation for 48 hours to Ringer solution without (white bar) or with (black 
bars) 1-50 µM oridonin. *** (p<0.001) indicate significant difference from the absence of oridonin (ANOVA). 
Ca2+ further stimulates cell membrane scrambling with subsequent phosphatidylserine exposure at 
the cell surface. Annexin V binding was employed to identify phosphatidylserine exposing 
erythrocytes. Annexin V binding in the absence and presence of 50 µM oridonin was visualized 
by confocal imaging (Fig. 40). The number of annexin V positive erythrocytes was indeed 
increased following oridonin treatment.  
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Fig. 40: Confocal images of PS-exposing erythrocytes with or without prior oridonin treatment 
Confocal microscopy of FITC-dependent fluorescence (upper panels) and light microscopy (lower panels) of human 
erythrocytes stained with FITC-conjugated Annexin-V-Fluos following 48 hours incubation in Ringer solution 
without (left panels) and with (right panels) 50 µM oridonin.  
FACS analysis was employed to quantify annexin V binding. As illustrated in Fig. 41A and 41B, 
exposure of erythrocytes for 48 hours to Ringer solution containing oridonin increased the 
percentage of annexin V binding erythrocytes, an effect reaching statistical significance at 25 µM 
oridonin.  
To determine hemolysis, the hemoglobin release into the supernatant was determined following 
exposure of the erythrocytes to Ringer solution without or with 1-50 µM oridonin. As shown in 
Fig. 41B, the exposure to oridonin was followed by hemolysis, an effect reaching statistical 
significance at 10 µM oridonin. The percentage of hemolytic erythrocytes remained, however, 
one order of magnitude smaller than the percentage of annexin V binding erythrocytes.  
An additional series of experiments explored whether oridonin-induced cell membrane 
scrambling was dependent on the presence of Ca2+. To this end, erythrocytes were exposed to 
oridonin in the presence or nominal absence of extracellular Ca2+. As illustrated in Fig. 41C, the 
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effect of oridonin on annexin V-binding was blunted, but not abolished in the nominal absence of 
Ca2+. In a further series of experiments, the Ca2+ permeable cation channels were inhibited by 
amiloride (1 mM). As shown in Fig. 41D, the addition of amiloride (1 mM) blunted, but did not 
abolish the effect of oridonin on annexin V-binding. 
Collectively, the experiments suggest that exposure of erythrocytes to oridonin increased 
intracellular Ca2+ activity, which in turn contributed to subsequent cell shrinkage and cell 
membrane scrambling. The residual cell membrane scrambling in the nominal absence of Ca2+ or 
in the presence of the cation channel blocker amiloride pointed, however, to an additional 
mechanism in the triggering of eryptosis following exposure to oridonin. 
 
Fig. 41: Effect of oridonin on phosphatidylserine exposure  
A. Original histogram of annexin V binding of erythrocytes following exposure for 48 hours to Ringer solution 
without (-, black line) and with (+, red line) presence of 50 µM oridonin. B. Arithmetic means ± SEM (n = 8) of 
erythrocyte annexin V binding following incubation for 48 hours to Ringer solution without (white bar) or with 
(black bars) presence of 1-50 µM oridonin. For comparison, arithmetic means ± SEM (n = 4) of the percentage of 
hemolysis are shown as grey bars. *(p<0.05), *** (p<0.001) indicate significant difference from the absence of 
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oridonin (ANOVA). C. Arithmetic means ± SEM (n = 8) of the percentage of annexin V-binding erythrocytes after a 
48 hours treatment with Ringer solution without (white bar) or with (black bars) 50 µM oridonin in the presence (left 
bars, +Ca2+) and absence (right bars, -Ca2+) of calcium. *** (p<0.001) indicate significant difference from the 
absence of oridonin (ANOVA), ### (p<0.001) indicates significant difference from the respective values in the 
presence of Ca2+. D. Arithmetic means ± SEM (n = 5) of the percentage of annexin V-binding erythrocytes after a 48 
hours treatment with Ringer solution without (white bar) or with (black bars) 50 µM oridonin in the absence (left 
bars) and presence (right bars) of 1 mM amiloride. *** (p<0.001) indicate significant difference from the absence of 
oridonin (ANOVA), ### (p<0.001) indicates significant difference from the respective values in the absence of 1 mM 
amiloride. 
As eryptosis is stimulated by energy depletion, cytosolic ATP concentration was determined in 
erythrocytes incubated for 48 hours without or with oridonin. For comparison, the ATP 
concentration was determined in erythrocytes exposed to glucose-free Ringer. As shown in Fig. 42, 
exposure to oridonin did not significantly modify cytosolic ATP concentration. In contrast, glucose 
withdrawal was followed by the expected decrease of ATP concentration.   
 
Fig. 42: Effect of oridonin on erythrocyte cytosolic ATP content 
Arithmetic means ± SEM (n = 4) of the ATP concentration after a 48 hours incubation in Ringer solution without 
(white bar) or with (black bars) oridonin at the indicated concentrations, or in glucose-depleted Ringer solution (grey 
bar, minus glucose) ** (p<0.01) indicates significant difference from control (absence of oridonin and presence of 
glucose) (ANOVA). 
 
Phosphatidylserine exposure and cell shrinkage are further known to be triggered by ceramide. 
Accordingly, additional experiments were performed to elucidate whether exposure to oridonin 
increases ceramide formation in erythrocytes. According to binding of FITC labelled anti-
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ceramide antibodies, ceramide formation was indeed increased by oridonin exposure, an effect 
reaching statistical significance at 10 µM oridonin concentration (Fig. 43). 
 
Fig. 43: Effect of oridonin on ceramide formation  
A. Original histogram of annexin V binding of erythrocytes following exposure for 48 hours to Ringer solution 
without (-, black line) and with (+, red line) presence of 50 µM oridonin. B. Arithmetic means ± SEM (n = 4) of 
ceramide abundance in erythrocytes following incubation for 48 hours to Ringer solution without (white bar) or with 
(black bars) presence of 1-50 µM oridonin. *(p<0.05), ** (p<0.01) indicate significant difference from the absence of 
oridonin (ANOVA). 
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7.2.3. Dicoumarol 
Cytosolic Ca2+ concentration in human erythrocytes was determined utilizing Fluo 3 fluorescence 
in FACS analysis. As illustrated in Fig. 44A and 44B, a 48 hours exposure to dicoumarol 
increased cytosolic Ca2+ concentration ([Ca2+]i), an effect reaching statistical significance at 20 
µM dicoumarol concentration. At higher concentration (30 µM) dicoumarol increased [Ca2+]i (by 
17.0 ± 3.3%, n = 4) within 1 hour. 
Fig. 44: Effect of dicoumarol on erythrocyte cytosolic Ca2+ concentration  
A. Original histogram of Fluo3 fluorescence in erythrocytes following exposure for 48 hours to Ringer´s solution 
without (-, black line) and with (+, red line) the presence of 30 µM dicoumarol. B. Arithmetic means ± SEM (n = 16) 
of the geo means (geometric mean of the histogram in arbitrary units) of Fluo3 fluorescence in erythrocytes exposed 
for 48 hours to Ringer´s solution without (white bar) or with (black bars) 1-30 µM dicoumarol. *** indicates 
significant difference (p<0.001) from the respective value in the absence of dicoumarol (ANOVA). 
Whole cell patch-clamp experiments were performed to elucidate whether dicoumarol influences 
cation ion channel activity. Replacing Ringer bath solution with Na-gluconate markedly 
increased, whereas replacing Na+ with NMDG or Ca2+ decreased currents in untreated control 
cells when recorded with Na-gluconate in the pipette solution. In addition, substitution of Na+ by 
the larger and less permeable cation NMDG+ shifted the reversal potentials of the current-voltage-
relationships (I/V) from ~0 mV in Ringer bath (Fig. 45 A) to about  -60 mV (Fig. 45 B). The data 
suggest the following rank of cation perm selectivity of the channels in control cells: Na+ > Ca2+ 
>> NMDG+. As illustrated in Fig. 45, dicoumarol (30 µM) treatment indeed significantly 
enhanced the cation conductance irrespective to the cation used in the bath solutions. The cation 
conductance following Cl-removal was also found to be more than 2 times higher in cells treated 
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with dicoumarol than in control cells (0.482 nS for dicoumarol-treated and 0.213 nS for control 
cells, respectively).  
Fig. 45: Effect of dicoumarol on cation channels in human erythrocytes. 
A. Mean (± SEM) of I/V relationships in erythrocytes incubated for 3-6 hours at 37 oC in Ringer bath solution in the 
absence (open squares, n = 18) or presence (closed triangles, n = 11) of  30 µM dicoumarol. Currents were recorded 
with the Na-gluconate pipette and Ringer (± 30 µM dicoumarol) bath solutions. B. Mean (± SEM) of I/V 
relationships (as in A) for the currents recorded in 180 mM NMDG-Cl bath solution (n = 18 for control and n = 11 
for 30 µM dicoumarol treated cells).  C. Mean (± SEM) of I/V relationships (as in A) for the currents recorded in 100 
mM CaCl2 bath solution (n = 16 for control and n = 10 for 30 µM dicoumarol treated cells).  D. Mean (± SEM) of I/V 
relationships (as in A) for the currents recorded in 150 mM Na-gluconate bath solution (n = 16 for control and n = 11 
for 30 µM dicoumarol treated cells). E. Mean (± SEM, n = 11-18) conductance (as calculated from the data in (A, B) 
for the inward currents by linear regression) in the absence (open bars) and presence (closed bar) of 30 µM 
dicoumarol. *, ** indicate significant difference (p<0.05, p<0.001) from the respective value in the absence of 
dicoumarol (t-test). 
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An increase of cytosolic Ca2+ concentration were expected to stimulate Ca2+ sensitive K+ channels 
leading to K+ exit, hyperpolarisation, Cl- exit and thus to cell shrinkage by cellular loss of KCl 
and osmotically obliged water. Cell volume was thus determined utilizing forward scatter in 
FACS analysis. As shown in Fig. 46A and 46B, a 48 hours exposure of erythrocytes to 
dicoumarol decreased the forward scatter, an effect reaching statistical significance at 10 µM 
dicoumarol. Thus, dicoumarol exposure was followed by cell shrinkage.  
Fig. 46: Effect of dicoumarol on erythrocyte forward scatter  
A. Original histogram of forward scatter of erythrocytes following exposure for 48 hours to Ringer´s solution without 
(-, black line) and with (+, red line) the presence of 30 µM dicoumarol. B. Arithmetic means ± SEM (n = 16) of the 
erythrocyte forward scatter following incubation for 48 hours in Ringer´s solution without (white bar) or with (black 
bars) 1-30 µM dicoumarol. *** (p<0.001) indicate significant difference from the absence of dicoumarol (ANOVA). 
An increase of cytosolic Ca2+ concentration was further expected to trigger cell membrane 
scrambling with phosphatidylserine exposure at the cell surface. Phosphatidylserine exposing 
erythrocytes were thus identified by annexin V binding. As apparent from Fig. 47, dicoumarol 
exposure increased the percentage of annexin V binding erythrocytes. The percentage of 
phosphatidylserine exposing erythrocytes was quantified in FACS analysis.  
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Fig. 47: Confocal images of PS-exposing erythrocytes exposed to dicoumarol 
Confocal microscopy of FITC-dependent fluorescence (upper panels) and light microscopy (lower panels) of human 
erythrocytes stained with FITC-conjugated Annexin-V-Fluos following 48 hours incubation in Ringer´s solution 
without (left panels) and with (right panels) 30 µM dicoumarol.  
As illustrated in Fig. 48A and 48B, the percentage of annexin V binding erythrocytes was higher 
following a 48 hours exposure of erythrocytes to Ringer´s solution containing dicoumarol than 
following a 48 hours exposure of erythrocytes to Ringer´s solution without dicoumarol. The 
difference of the percentage annexin V binding erythrocytes between the presence and absence of 
dicoumarol reached statistical significance at ≥10 µM dicoumarol.  
Exposure to dicoumarol was further followed by hemolysis, reflected by hemoglobin release. As 
illustrated in Fig. 48B, the exposure to dicoumarol was followed by an increase of hemoglobin 
release, an effect reaching statistical significance at 1 µM dicoumarol concentration. The 
percentage of hemolysed erythrocytes remained, however, almost one magnitude smaller than the 
percentage of phosphatidylserine exposing erythrocytes. 
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Fig. 48: Effect of dicoumarol on phosphatidylserine exposure and erythrocyte membrane integrity 
A. Original histogram of annexin V binding of erythrocytes following exposure for 48 hours to Ringer´s solution 
without (-, black line) and with (+, red line) presence of 30 µM dicoumarol. 
B. Arithmetic means ± SEM (n = 16) of erythrocyte annexin V binding following incubation for 48 hours in Ringer´s 
solution without (white bar) or with (black bars) the presence of 1-30 µM dicoumarol. For comparison, arithmetic 
means ± SEM (n = 4) of the percentage of hemolysis is shown as grey bars. *, **, *** (p<0.05, p<001, p<0.001) 
indicate significant difference from the absence of dicoumarol (ANOVA). 
Further experiments were done in the absence of extracellular Ca2+ to clarify, whether cell 
membrane scrambling depended on Ca2+ entry. To this end the percentage of annexin V binding 
erythrocytes was determined following a 48 hours treatment with dicoumarol in the presence and 
nominal absence of extracellular Ca2+. As shown in Fig. 49, the effect of dicoumarol on annexin 
V-binding was virtually abolished in the nominal absence of Ca2+.  
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Fig. 49: Effect of Ca2+ withdrawal on dicoumarol induced phosphatidylserine exposure 
Arithmetic means ± SEM (n = 4) of the percentage of annexin V-binding erythrocytes after a 48 hours treatment with 
Ringer´s solution without (white bar) or with (black bars) 30 µM dicoumarol in the presence (left bars, +Ca2+) and 
absence (right bars, -Ca2+) of calcium. *** (p<0.001) indicate significant difference from the absence of dicoumarol 
(ANOVA), ### indicates significant difference (p<0.001) from the respective values in the presence of Ca2+. 
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8. DISCUSSION 
8.1. Stimulation of suicidal death of erythrocytes by mycotoxins 
8.1.1. Enniatin A 
The observations from my studies reveal a novel action of the mycotoxin enniatin A, i.e. ATP 
depletion, triggering of Ca2+ entry, cell shrinkage and cell membrane scrambling in human 
erythrocytes. Moreover, the present observations reveal that enniatin A augments the Ca2+ entry and 
cell membrane scrambling following energy depletion. The concentrations required for those 
effects are well in the range of those triggering apoptosis of nucleated cells (Watjen, Debbab et al. 
2009) and to be toxic in vivo (McKee, Bokesch et al. 1997).  
As indicated earlier (Klarl, Lang et al. 2006) Ca2+ entry into erythrocytes is stimulated by phorbol 
esters and inhibited by staurosporine and chelerythrine, pointing to regulation of Ca2+ entry by 
protein kinase C (PKC). The kinase is activated and thus Ca2+ entry stimulated by ATP depletion 
(Klarl, Lang et al. 2006) . The effects of energy depletion were blunted but not abolished in the 
presence of the kinase inhibitors staurosporine or calphostin C and mimicked by PKC stimulator 
phorbol-12-myristate-13-acetate or the phosphatase inhibitor okadaic acid (Klarl, Lang et al. 
2006). The enniatin A-induced Ca2+ entry thus presumably results in large part from the severe 
ATP depletion. Along those lines the cell membrane scrambling was blunted by staurosporine.  
An increase of cytosolic Ca2+ concentration is well known to trigger erythrocyte membrane 
scrambling (Berg, Engels et al. 2001, Bratosin, Estaquier et al. 2001). According to the present 
observations, enniatin A further augments the increase of cytosolic Ca2+ concentration following 
energy depletion. The increase of Ca2+ concentration following enniatin A exposure presumably 
results from stimulation of Ca2+ entry, which is accomplished by Ca2+ permeable cation channels 
involving TRPC6 (Foller, Kasinathan et al. 2008). Accordingly, the Ca2+ entry is blunted by the 
addition of cation channel blocker amiloride. The effect of enniatin A on cell membrane scrambling 
is, however, only blunted but not fully abolished in the nominal absence of extracellular Ca2+ 
indicating that the effect of enniatin A on cell membrane scrambling is in part but not completely 
accounted for by its effect on Ca2+ entry. 
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The effect of enniatin A is not significantly modified by the pancaspase inhibitor zVAD.  This 
result contrasts the observations in nucleated cells, where the apoptotic effect of enniatins appears 
to be at least partially dependent on caspase activation (Hyun, Lee et al. 2009). Erythrocytes do 
express caspases (Bratosin, Estaquier et al. 2001, Mandal, Moitra et al. 2002), which could be 
activated by oxidative stress but do not participate in the stimulation of cell membrane scrambling by 
Ca2+ (Weil, Jacobson et al. 1998, Berg, Engels et al. 2001, Lang, Myssina et al. 2004).  As illustrated 
in Fig. 17E, zVAD does significantly blunt the annexin V binding following exposure of 
erythrocytes following oxidation, indicating that the substance was able to inhibit erythrocyte 
caspases.   
The increase of erythrocyte Ca2+ concentration is expected to activate Ca2+ sensitive K+ channels 
(Bookchin, Ortiz et al. 1987, Brugnara, de Franceschi et al. 1993) leading to subsequent cell 
shrinkage due to exit of K+, hyperpolarisation of the cell membrane, exit of Cl- and osmotically 
obliged water (Lang, Kaiser et al. 2003). Enniatin A exposure indeed decreased the erythrocyte 
forward scatter and thus led to cell shrinkage. Somewhat surprisingly, higher concentrations of 
enniatin A blunted the effect of glucose depletion on cell volume. Possibly, the severe ATP depletion 
following enniatin A treatment in the absence of glucose impaired the Na+/K+ ATPase activity 
leading to a decline of cellular K+ concentration and thus to dissipation of the K+ gradient across the 
cell membrane. Following loss of K+ gradient across the cell membrane, the activation of Ca2+ 
sensitive K+ channels fails to trigger K+ exit, hyperpolarization and Cl- exit. Thus, in K+ depleted 
erythrocytes Ca2+ entry fails to trigger cell shrinkage. The swelling following exposure of ATP 
depleted erythrocytes to high (5 µM) concentrations of enniatin A could be explained by Na+ entry 
through the Ca2+ permeable cation channels.    
Similar to glucose depletion, other triggers of phospholipid scrambling could compound the effect of 
enniatin A. Excessive phospholipid scrambling is observed in a variety of clinical disorders (Lang, 
Gulbins et al. 2008)  including iron deficiency(Kempe, Lang et al. 2006), phosphate depletion(Birka, 
Lang et al. 2004), Hemolytic Uremic Syndrome (Lang, Beringer et al. 2006), sepsis(Kempe, Akel 
et al. 2007), sickle cell disaease (Lang, Kasinathan et al. 2009). Malaria (Foller, Bobbala et al. 
2009, Lang, Kasinathan et al. 2009), Wilson’s disease(Lang, Schenck et al. 2007) and possibly 
metabolic syndrome (Zappulla 2008). Moreover, phospholipid scrambling is triggered by a variety 
of further xenobiotics and endogeneous substances (Mahmud, Foller et al. 2009, Bhavsar, 
Bobbala et al. 2010). Accelerated erythrocyte phospholipid scrambling may result in development 
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of anemia (Lang, Gulbins et al. 2008). Clinically overt anemia will however develop only, if the 
accelerated clearance of eryptotic erythrocytes cannot be compensated by increased production of 
new erythrocytes. The loss of circulating erythrocytes is followed by release of erythropoietin and 
subsequent hormonal stimulation of erythrocyte formation, which is apparent from the increase of 
the reticulocyte number (Foller, Feil et al. 2008, Foller, Sopjani et al. 2009). In addition to 
triggering anemia, erythrocyte phospholipid scrambling may impede microcirculation due to 
adherence of phosphatidylserine-exposing erythrocytes to the vascular wall (Wood, Gibson et al. 
1996, Andrews and Low 1999).Moreover, eryptotic erythrocytes may stimulate blood clotting 
(Andrews and Low 1999, Zwaal, Comfurius et al. 2005, Chung, Bae et al. 2007). 
In conclusion, the present observations disclose that enniatin A stimulates erythrocyte phospholipid 
scrambling and augments phospholipid scrambling during energy depletion. Those effects 
presumably contribute to the toxicity of this mycotoxin food contaminant. 
8.1.2. Ochratoxin A 
The present study reveals a novel effect ochratoxin A, i.e. the stimulation of erythrocyte shrinkage 
and plasma membrane scrambling. Thus, ochratoxin A triggers suicidal erythrocyte death or 
eryptosis. The concentration required for the stimulation of cell membrane scrambling is 2.5 µM, 
which is well in the range of the concentrations encountered in vivo (Alvarez, Gil et al. 2004). A 
plasma concentration of 2 µM, for instance, has been reported following treatment of Wistar rats 
with 450 µg/kg body weight (Alvarez, Gil et al. 2004). Thus, the present observations may be 
relevant for the in vivo toxicity of ochratoxin A. On the other hand, effects of ochratoxin A in 
nanomolar concentrations have been described (Gekle, Sauvant et al. 2005).   
Ochratoxin A is at least in part effective by increase of cytosolic Ca2+-activity, which presumably 
results from Ca2+-entry from extracellular space. Thus, ochratoxin A most likely activates Ca2+-
permeable cation channels. The channels have earlier been shown to involve the transient receptor 
potential channel TRPC6 (Foller, Kasinathan et al. 2008). The channels are known to be activated 
by oxidative stress (Bhavsar, Bobbala et al. 2010).  
Increase of cytosolic Ca2+-activity results in activation of Ca2+-sensitive K+-channels [33, 49] 
leading to K+-exit following its chemical gradient. The resulting cell membrane hyperpolarization 
drives Cl--exit, the cellular KCl-loss is paralleled by exit of osmotically obliged water and thus by 
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cell shrinkage (Lang, Duranton et al. 2003). The decrease of erythrocyte volume is reflected by a 
decrease of forward scatter.  
Increased cytosolic Ca2+-activity further triggers cell membrane scrambling with subsequent 
phosphatidylserine exposure at the erythrocyte surface (Berg, Engels et al. 2001, Bratosin, Estaquier 
et al. 2001, Lang, Duranton et al. 2003). The ochratoxin A induced cell membrane scrambling is 
significantly blunted by removal of extracellular Ca2+, indicating that ochratoxin A is at least 
partially effective by stimulating Ca2+-entry from extracellular space. Removal of extracellular Ca2+ 
does, however, not fully abrogate the ochratoxin A induced cell membrane scrambling, indicating 
that one or more additional mechanisms may be involved in the stimulation of cell membrane 
scrambling by ochratoxin A.  
Such an additional mechanism contributing to the ochratoxin A induced cell membrane 
scrambling is the stimulation of ceramide formation. Ceramide sensitizes the scrambling 
machinery for Ca2+ and may by itself stimulate cell membrane scrambling in erythrocytes (Lang, 
Myssina et al. 2004, Lang, Gulbins et al. 2010). Moreover, ceramide is a powerful stimulator of 
apoptosis (Kornhuber, Tripal et al. 2010). Ceramide participates in the pathophysiology of several 
diseases, including diabetes (Zhao, Przybylska et al. 2007, Holland and Summers 2008), Wilson’s 
disease (Lang, Schenck et al. 2007), multiple sclerosis (Walter and Fassbender 2010), major 
depression (Kornhuber, Tripal et al. 2010), Parkinson’s disease (Arboleda, Huang et al. 2007), 
Alzheimer’s disease (de la Monte 2009, Tong, Neusner et al. 2009, Kornhuber, Tripal et al. 
2010), cardiovascular disease (Kuebler, Yang et al. 2010, Li, Becker et al. 2010), cystic fibrosis 
(Becker, Grassme et al. 2010), lung inflammation, fibrosis and infection(Dhami, He et al. 2010). 
However, inhibition of sphingomyelinase with amitriptylin did not prevent the stimulation of cell 
membrane scrambling by ochratoxin A. Thus, activation of the sphingomyelinase may contribute 
to but does not account for the stimulation of cell membrane scrambling by ochratoxin A.   
Eryptosis may be pathophysiologically relevant. Phosphatidylserine exposing erythrocytes adhere 
to endothelial CXCL16/SR-PSO (Borst, Abed et al. 2012). The erythrocyte adhesion to the 
vascular wall is expected to compromize microcirculation (Wood, Gibson et al. 1996, Borst, Abed 
et al. 2012). Phosphatidylserine exposing erythrocytes are further known to foster blood clotting 
(Andrews and Low 1999, Zwaal, Comfurius et al. 2005, Chung, Bae et al. 2007) and thus to 
increase the risk of thrombosis. Eventually, phosphatidylserine exposing erythrocytes are 
engulfed and thus cleared from circulating blood (Lang, Gulbins et al. 2008). To the extent that 
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the accelerated loss of erythrocytes is not compensated by a similar increase of erythropoiesis, 
enhanced eryptosis may result in anemia (Lang, Gulbins et al. 2008). Thus, the present 
observations could well explain the ochratoxin induced anemia known since several decades 
(Huff, Chang et al. 1979, Stoev, Anguelov et al. 2000).  
The present observations may be relevant not only for the ochratoxin A induced erythrocyte 
death, but may, in addition, shed additional light on the mechanisms underlying ochratoxin A 
induced apoptosis of nucleated cells. Evidence for the involvement of Ca2+ in the stimulation of 
apoptosis has been provided before [29]. To the best of our knowledge, the involvement of 
ceramide formation in ochratoxin A toxicity has never been reported. In view of the present 
observations, ceramide may be involved in ochratoxin A incuced apoptosis of nucleated cells.       
In conclusion, the exposure of erythrocytes to ochratoxin A leads to Ca2+ entry and ceramide 
formation with subsequent triggering of cell membrane scrambling and cell shrinkage. Thus, 
ochratoxin A stimulates eryptosis, the suicidal death of erythrocytes.   
8.1.3. Zearalenone 
The present observations uncover a novel effect of zearalenone, i.e. triggering of eryptosis, the 
suicidal death of erythrocytes. Exposure of human erythrocytes to zearalenone triggered the two 
hallmarks of eryptosis, i.e. erythrocyte shrinkage and erythrocyte membrane scrambling. The 
concentrations required were one order of magnitude higher (10-25 µM) than the concentrations 
found in blood of the common population (Pillay, Chuturgoon et al. 2002). The recommended 
safe human intake is estimated to be 0.05 µg/kg of body weight per day (Bennett and Klich 2003). 
At least in theory the concentration required for eryptosis may be reached by individuals exposed 
to cereals with excessive mycotoxin content. 
Zearalenone exposure decreased cell volume most likely by stimulating Ca2+ entry with subsequent 
increase of cytosolic Ca2+ activity. The increased cytosolic Ca2+ concentration activates Ca2+ 
sensitive K+ channels (Bookchin, Ortiz et al. 1987, Brugnara, de Franceschi et al. 1993) leading to 
cell membrane hyperpolarization, potential driven Cl- exit and thus cellular loss of KCl together with 
osmotically obliged water (Lang, Kaiser et al. 2003). 
The increase of cytosolic Ca2+ activity further accounted in large part for the stimulation of cell 
membrane scrambling. Accordingly, zearalenone induced cell membrane scrambling was virtually 
abrogated in the absence of extracellular Ca2+. Most xenobiotics known to trigger eryptosis are 
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effective in large part by increasing cytosolic Ca2+ activity (Lang, Gulbins et al. 2008). 
Circumstantial evidence suggests that Ca2+ enters into erythrocytes in part through Ca2+ permeable 
non-selective cation channels involving the transient receptor potential channel TRPC6 (Foller, 
Kasinathan et al. 2008). The Ca2+ permeable erythrocyte cation channels include oxidative stress 
(Brand, Sandu et al. 2003). Zearalenone is known to induce oxidative stress (Bouaziz, Sharaf El 
Dein et al. 2008, Bouaziz, Martel et al. 2009, Banjerdpongchai, Kongtawelert et al. 2010, Salah-
Abbes, Abbes et al. 2010, Yu, Zheng et al. 2011) and to increase cytosolic Ca2+ concentration 
(Vlata, Porichis et al. 2006) in nucleated cells. 
Circulating eryptotic erythrocytes are rapidly cleared from from blood (Lang, Gulbins et al. 
2008). Thus, even after stimulation of eryptosis, the percentage of eryptotic erythrocytes remains 
low in vivo. The accelerated loss of eryptotic erythrocytes following in vivo stimulation of 
erythrocytes may lead to anemia (Lang, Gulbins et al. 2008). Moderate stimulation of eryptosis 
may, however, be fully compensated by parallel stimulation of erythrocyte formation (Lang, 
Gulbins et al. 2008). Anemia develops as soon as the rate of eryptosis exceeds the formation of 
new erythrocytes, (Lang, Gulbins et al. 2008). 
Phosphatidylserine exposing erythrocytes may adhere to endothelial CXCL16/SR-PSO (Borst, 
Abed et al. 2012) and thus attach to the vascular wall. Moreover, phosphatidylserine exposing 
erythrocytes may trigger blood clotting and thus lead to thrombosis (Andrews and Low 1999, 
Zwaal, Comfurius et al. 2005, Chung, Bae et al. 2007). Phosphatiddylserine exposing 
erythrocytes may thus compromize microcirculation (Wood, Gibson et al. 1996, Andrews and 
Low 1999, Closse, Dachary-Prigent et al. 1999, Gallagher, Chang et al. 2003, Pandolfi, Di Pietro 
et al. 2007, Borst, Abed et al. 2012). 
In conclusion, exposure of human erythrocytes to zearalenone stimulates Ca2+ entry, leading to 
eryptosis, the suicidal erythrocyte death characterized by cell membrane scrambling and cell 
shrinkage. 
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8.2. Stimulation of suicidal death of erythrocytes by phytochemicals 
8.2.1. Withaferin A 
According to the present observations withaferin A triggers eryptosis, the suicidal death of 
erythrocytes. Withaferin A exposure leads to the two hallmarks of eryptosis. i.e. erythrocyte 
membrane scrambling and erythrocyte shrinkage. The concentration required for the effect on cell 
membrane scrambling is in the range of the concentrations effective against tumor cells (Samadi, 
Tong et al. 2010) and is only slightly above the concentrations observed in vivo after therapeutic 
administration of withaferin A (Thaiparambil, Bender et al. 2011).  
Withaferin A increases cytosolic Ca2+ activity, an effect pointing to activation of Ca2+ permeable 
cation channels. Erythrocytes do express Ca2+ permeable unselective cation channels (Lang, Gulbins 
et al. 2008), which are in part dependent on the expression of transient receptor potential channel 
TRPC6 (Foller, Kasinathan et al. 2008). The cation channels have previously been shown to be 
activated by oxidative stress (Lee, Um et al. 2009, Hahm, Moura et al. 2011, Mayola, Gallerne et 
al. 2011, Yang, Choi et al. 2011). According to 2’,7’ dichlorodihydrofluorescein diacetate 
(DCFDA) fluorescence, withhaferin A indeed induces oxidative stress which could well account 
for activation of the channels.     
The increase of cytosolic Ca2+ activity presumably contributes to or even accounts for the 
observed cell shrinkage. Erythrocytes do express Ca2+ sensitive K+ channels (Lang et al., 2008). 
Activation of those channels leads to exit of K+ following its chemical gradient which in turn leads to 
cell membrane hyperpolarisation and potential driven Cl- exit. The cellular loss of KCl with 
osmotically obliged water leads to cell shrinkage (Lang, Gulbins et al. 2008), which is reflected by 
the observed decrease of forward scatter.  
An increase of cytosolic Ca2+ activity further triggers cell membrane scrambling with 
phosphatidylserine exposure at the erythrocyte surface (Lang, Gulbins et al. 2008). The cell 
membrane scrambling following treatment with withaferin A is blunted, but not abrogated by 
removal of extracellular Ca2+. Thus, Ca2+ entry contributes to but does not fully account for the 
triggering of the cell membrane scrambling following withaferin treatment and withaferin A thus 
induces cell membrane scrambling by some additional mechanism(s).  
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Withaferin A treatment was further followed by an increase in the formation of ceramide, which 
has previously been shown to stimulate erythrocyte membrane scrambling (Lang, Gulbins et al. 
2010). Ceramide similarly triggers apoptosis of nucleated cells (Kornhuber, Tripal et al. 2010) 
and ceramide formation participates in the pathophysiology of several clinical disorders including 
lung inflammation, fibrosis and infection (Dhami, He et al. 2010), cystic fibrosis(Becker, 
Grassme et al. 2010), cardiovascular disease (Kuebler, Yang et al. 2010, Li, Becker et al. 2010), 
Wilson’s disease (Lang, Schenck et al. 2007), multiple sclerosis (Walter and Fassbender 2010), 
major depression (Kornhuber, Tripal et al. 2010), Parkinson’s disease (Arboleda, Huang et al. 
2007), Alzheimer’s disease (de la Monte 2009, Tong, Neusner et al. 2009, Kornhuber, Tripal et 
al. 2010) and diabetes (Zhao, Przybylska et al. 2007, Holland and Summers 2008, Zigmond, 
Zangen et al. 2009). Thus, withaferin induced ceramide formation may affect survival and 
function of a wide variety of cells. 
Phosphatidylserine exposing erythrocytes are engulfed by macrophages (Lang, Gulbins et al. 
2008) and are thus eventually cleared from circulating blood (Lang, Gulbins et al. 2008). 
Accordingly, excessive eryptosis leads to anemia (Lang, Gulbins et al. 2008). Phosphatidylserine 
exposing erythrocytes further adhere to endothelial CXCL16/SR-PSOX (Borst, Abed et al. 2012). 
The adherance of erythrocytes to the vascular wall may impair microcirculation (Borst, Abed et al. 
2012). Moreover, phosphatidylserine exposing erythrocytes foster blood clotting (Zwaal, 
Comfurius et al. 2005, Chung, Bae et al. 2007). Accordingly, excessive eryptosis may result in 
thrombosis.  
In conclusion, withaferin A triggers Ca2+ entry, oxidative stress and ceramide formation, effects 
triggering eryptosis, which is characterized by cell membrane scrambling and cell shrinkage. Thus, 
withaferin A triggers not only apoptosis in nucleated cells with mitochondria, but is similarly 
effective in cells lacking those important organelles in the machinery of apoptosis.  
8.2.2. Oridonin 
The present observations unravel a completely novel effect of oridonin, i.e. increase of cytosolic Ca2+ 
activity and stimulation of ceramide formation in erythrocytes, events eventually leading to 
eryptosis, the suicidal death of erythrocyte. Oridonin has a minor stimulating effect on hemolysis.  
Oridonin induced annexin V binding is blunted in the nominal absence of Ca2+, indicating that the 
cell membrane scrambling is in part secondary to the increase of cytosolic Ca2+ activity. According 
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to earlier observations (Foller, Kasinathan et al. 2008), Ca2+ enters the erythrocytes through Ca2+ 
permeable cation channels involving the transient receptor potential channel TRPC6. To the best 
of our knowledge, an effect of oridonin on ion channels or on cytosolic Ca2+ activity has never 
been reported.  
The increase of erythrocyte Ca2+ concentrations activates Ca2+ sensitive K+ channels (Bookchin, 
Ortiz et al. 1987, Brugnara, de Franceschi et al. 1993) with subsequent K+ exit, hyperpolarisation of 
the cell membrane, Cl- exit, and cellular loss of KCl with osmotically obliged water (Lang, Kaiser et 
al. 2003). Oridonin thus decreases the forward scatter.  
The effect of oridonin on cell membrane is not completely abrogated in the nominal absence of 
extracellular Ca2+. Thus, oridonin must have an additional effect on erythrocytes. As a matter of 
fact, oridonin stimulates the formation of ceramide, which has previously been shown to 
participate in the triggering of apoptosis and/or cell membrane scambling in a variety of cells 
(Arana, Gangoiti et al. 2010, Nikolova-Karakashian and Rozenova 2010) including neurons 
(Jana, Hogan et al. 2009, Arboleda, Cardenas et al. 2010), T-lymphocytes (Gulbins, Szabo et al. 
1997), hepatocytes (Lang, Schenck et al. 2007), epithelial cells (Teichgraber, Ulrich et al. 2008) 
and erythrocytes (Lang, Myssina et al. 2004, Lang, Schenck et al. 2007, Lang, Gulbins et al. 
2010). Oridonin does not induce energy depletion, another potential stimulator of eryptosis (Klarl, 
Lang et al. 2006). 
In nucleated cells, oridonin triggers apoptosis in part by affecting the mitochondria (Zhang, Wu et 
al. 2004, Li, Cui et al. 2007, Huang, Wu et al. 2008, Li, Wu et al. 2008). Erythrocytes are, 
however, devoid of mitochondria and the stimulation of Ca2+ entry and subsequent triggering of 
cell shrinkage as well as cell membrane scrambling do not require prior depolarization of the 
mitochondrial membrane.  
In nucleated cells, oridonin is further partially effective through inhibition of the transcription 
factor NFκB (Hsieh, Wijeratne et al. 2005, Ikezoe, Yang et al. 2005, Cho, Moon et al. 2009, 
Zhang, Wu et al. 2009, Gatsinzi and Iverfeldt 2011, Ma, Xu et al. 2011) As erythrocytes lack 
nuclei, the observed eryptosis cannot be secondary to altered gene expression. It is noteworthy, 
though, that NFκB inhibitors Bay 11-7082 and Parthenolide have most recently been shown to 
trigger eryptosis (Ghashghaeinia, Toulany et al. 2011). Whether the effect of the inhibitors is 
indeed caused by NFκB inhibition, remained, however, elusive.    
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Oridonin may augment the eryptosis resulting from other causes (Lang, Gulbins et al. 2008) such as 
iron deficiency (Kempe, Lang et al. 2006), phosphate depletion (Birka, Lang et al. 2004), sepsis 
(Kempe, Akel et al. 2007), Hemolytic Uremic Syndrome (Lang, Beringer et al. 2006), sickle cell 
disease  (Lang, Kasinathan et al. 2009) malaria (Lang, Schenck et al. 2007, Koka, Bobbala et al. 
2009, Siraskar, Ballal et al. 2010), Wilson’s disease (Lang, Schenck et al. 2007) and presumably 
metabolic syndrome (Zappulla 2008). Moreover, oridonin may potentiate the eryptotic effect of 
other xenobiotics (Mahmud, Mauro et al. 2009, Bhavsar, Bobbala et al. 2010).  
Eryptosis may result in anemia (Lang, Gulbins et al. 2008) and adherence of phosphatidylserine-
exposing erythrocytes to the vascular wall may compromise microcirculation (Wood, Gibson et al. 
1996, Andrews and Low 1999). Eryptotic erythrocytes may further trigger blood clotting (Andrews 
and Low 1999, Zwaal, Comfurius et al. 2005, Chung, Bae et al. 2007). In conclusion, the present 
study reveals a completely novel effect of oridonin, i.e. increase of cytosolic Ca2+ activity and 
stimulation of ceramide formation in erythrocytes, effects eventually triggering eryptosis, the suicidal 
erythrocyte death.   
8.2.3. Dicoumarol 
The present study reveals a novel side effect of dicoumarol, i.e. activation of the erythrocyte cation 
channel with subsequent triggering of Ca2+ entry into and eryptosis of human erythrocytes. The 
dicoumarol concentrations required for those effects are in the range of those approached in vivo. 
Plasma concentrations of dicoumarol have been reported to approach 7.7 ± 1.1 µg/ml or 
approximately 20 µM (Levy, Lai et al. 1978). 
The eryptosis is apparently the result of Ca2+ entry with subsequent increase of the cytosolic Ca2+ 
concentration. At higher dicoumarol concentrations activation of current and Ca2+ entry are observed 
within a few hours and could thus account for the triggering of cell membrane scrambling within 48 
hours. Accordingly, the phosphatidylserine exposure is abrogated in the absence of extracellular 
Ca2+. The Ca2+ entry into erythrocytes involves TRPC6 (Foller, Kasinathan et al. 2008). 
Dicoumarol may stimulate the channels indirectly. For instance, dicoumarol may induce oxidative 
stress (Collier and Pritsos 2003, Jing, Yi et al. 2004, Vad, Yount et al. 2009), which in turn 
activates the erythrocyte cation channels (Duranton, Huber et al. 2002). On the other hand, 
dicoumarol may counteract oxidation (Mangelus, Kroyter et al. 2001, Hasegawa, Bando et al. 
2004). Thus, the mechanism of channel activation remains elusive. Whatever mechanism 
 96 
involved in channel activation, the increase of cytosolic Ca2+ concentration triggers erythrocyte 
membrane scrambling with subsequent phosphatidylserine exposure at the cell surface (Berg, Engels 
et al. 2001, Bratosin, Estaquier et al. 2001). At higher concentrations (30 µM), dicoumarol may, in 
addition, stimulate the formation of ceramide (data not shown), which sensitizes the cell membrane 
for the cell membrane scrambling effect of cytosolic Ca2+ (Lang, Myssina et al. 2004, Lang, Gulbins 
et al. 2010). 
Cytosolic Ca2+ further activates Ca2+ sensitive K+ channels (Bookchin, Ortiz et al. 1987, Brugnara, 
de Franceschi et al. 1993) with subsequent exit of K+, hyperpolarisation of the cell membrane, exit of 
Cl- and thus cellular loss of KCl with osmotically obliged water (Lang, Kaiser et al. 2003). Along 
those lines, exposure of erythrocytes to dicoumarol decreased the erythrocyte forward scatter, an 
observation pointing to cell shrinkage.  
Dicoumarol may exacerbate eryptosis triggered in the course of several clinical conditions (Lang, 
Gulbins et al. 2008) including iron deficiency (Kempe, Lang et al. 2006), phosphate depletion 
(Birka, Lang et al. 2004), Hemolytic Uremic Syndrome (Lang, Beringer et al. 2006), sepsis 
(Kempe, Akel et al. 2007), sickle cell disaease (Lang, Kasinathan et al. 2009). Malaria (Foller, 
Bobbala et al. 2009, Koka, Bobbala et al. 2009, Lang, Kasinathan et al. 2009, Bobbala, Alesutan 
et al. 2010, Siraskar, Ballal et al. 2010), Wilson’s disease (Lang, Schenck et al. 2007) and 
possibly metabolic syndrome (Zappulla 2008). Eryptosis is further stimulated by a wide variety of 
small molecules (Braun, Foller et al. 2009, Gatidis, Foller et al. 2009, Mahmud, Foller et al. 2009, 
Bhavsar, Bobbala et al. 2010, Bhavsar, Eberhard et al. 2010, Eberhard, Ferlinz et al. 2010). The pro 
eryptotic effect of dicoumarol could be compounded in those clinical conditions and in the 
presence of those chemicals.  
Erythrocyte phospholipid scrambling fosters the clearance of affected erythrocytes from 
circulating blood (Lang, Gulbins et al. 2008). To the extent that the loss of erythrocytes cannot be 
compensated by release of erythropoietin and subsequent hormonal stimulation of erythrocyte 
formation (Foller, Feil et al. 2008, Foller, Sopjani et al. 2009) the loss of erythrocytes may lead to 
overt anemia. Moreover, erythrocyte phospholipid scrambling may foster adherence of 
phosphatidylserine-exposing erythrocytes to the vascular wall and thus impede microcirculation 
(Wood, Gibson et al. 1996, Andrews and Low 1999). Eryptotic erythrocytes may further stimulate 
blood clotting (Andrews and Low 1999, Zwaal, Comfurius et al. 2005, Chung, Bae et al. 2007). 
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At least in theory, dicoumarol may similarly stimulate Ca2+ entry into nucleated cells, which may 
trigger of apoptosis (Berridge, Lipp et al. 2000, Svoboda, Pruetting et al. 2009). Moreover, 
apoptosis may be triggered by ceramide (Arboleda, Huang et al. 2007, Lang, Schenck et al. 2007, 
Teichgraber, Ulrich et al. 2008) . Thus, the ability of dicoumarol to stimulate Ca2+ entry and 
generate ceramide formation may result in apoptosis. 
In conclusion, the present observations disclose that dicoumarol exposure leads to cell shrinkage and 
cell membrane scrambling, effects largely due to Ca2+ entry. 
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